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ABSTRACT 
 
Cancer is a heterogeneous disease with discrete oncogenic mechanisms. P53 mutation 
is the most common oncogenic mutation in many cancers including breast cancer. This 
dissertation focuses on fundamental genetic alterations enforced by p53 mutation as an 
indirect target. p53 mutation upregulates the mevalonate pathway genes altering 
cholesterol biosynthesis and prenylation. Prenylation, a lipid modification, is required for 
small GTPases signaling cascades. Project 1 demonstrates that prenylation inhibition can 
specifically target cells harboring p53 mutation resulting in reduced tumor proliferation and 
migration. Mutating p53 is associated with Ras and RhoA activation and statin prevents 
this activity by inhibiting prenylation. Ras-related pathway genes were selected from the 
transcriptomic analysis for evaluating correlation to statin sensitivity. A gene signature of 
seventeen genes and TP53 genotype (referred to as MPR signature) is generated to 
predict response to statins. MPR signature is validated through two datasets of drug 
screening in cell lines. As advancements in targeted gene modification are rising, the 
CRISPR-Cas9 technology has emerged as a new cancer therapeutic strategy. One of the 
important risk factors in gene therapy is the immune recognition of the exogenous 
therapeutic tool, resulting in obstruction of treatment and possibly serious health 
consequences. Project 2 describes a method development that can potentially improve 
the safety and efficacy of gene-targeting proteins. A cohort of 155 healthy individuals was 
screened for pre-existing B cell and T cell immune response to the S. pyogenes Cas9 
protein. We detected antibodies against Cas9 in more than 10% of the healthy population 
and identified two immunodominant T cell epitopes of this protein. A de-immunized Cas9 
that maintains the wild-type functionality was engineered by mutating the identified T cell 
  ii 
epitopes. The gene signature and method described here have the potential to improve 
strategies for genome-driven tumor targeting.  
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CHAPTER 1 
INTRODUCTION 
 
Discovery of gene mutations necessary for cancer initiation and progression have shown 
that tumors can demand a required mutation using the power of selection. One of the 
genes commonly mutated across all cancers is TP53, known as “the guardian of the 
genome”, leading to genome instability and facilitating more mutations generation 
(Bieging, Mello, & Attardi, 2014). With some exceptions, proteins recruited by a tumor cell 
also play critical roles in normal cell and are difficult to target. More and more evidence is 
being collected with the message that metabolic alteration is inherent to oncogenic 
activation (Hao et al., 2016; Jones & Thompson, 2009; Lee et al., 2014; Levine & Puzio-
Kuter, 2010). Although direct targeting the oncogenes is challenging and most likely 
replaceable by other oncogenes, synthetic lethal targeting is often the way to target tumor 
cells (Luo et al., 2009; Mendes-Pereira et al., 2009; Scholl et al., 2009).  Synthetic lethality 
is when targeting two oncogenes separately is not applicable but targeting simultaneously 
is significantly effective.  Metabolic changes enforced by certain oncogenes can be 
detected for synthetic lethality and be targeted for prominent results. 
This chapter describes a background on the metabolic requirements of cancer and 
the current understanding of the cancer mechanisms of controlling metabolism. First, 
some of the fundamental knowledge in the field is reviewed and then p53 tumor 
suppressor and its critical role in regulation of metabolism is explained. To further discuss 
the Ras and Rho collaboration with p53, this chapter explains the importance of small 
GTPases and the lipid modification necessary for their function. At the end of this chapter, 
current drugs and the clinical relevance is discussed.  
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1.1. CANCER CELL METABOLISM 
 
It has been about a century since metabolic alteration in tumors has been detected and 
described by Otto Warburg (Koppenol, Bounds, & Dang, 2011). He showed tumor tissues 
prefer glycolysis over the more efficient ATP production pathway, oxidative 
phosphorylation, even at the presence of extra oxygen. Today, aerobic glycolysis is 
accepted as a hallmark of cancer and glucose uptake is routinely used by 
fluorodeoxyglucose positron emission tomography (FDG-PET) in clinical diagnostic 
settings (Pavlova & Thompson, 2016). Metabolic alterations by tumors are applied to 1- 
elevate the metabolite influx (Lieberman et al., 2011; Thompson, 2011), 2- consume the 
nutrients in tumor preference metabolic pathway (Commisso et al., 2013; Conrad & Sato, 
2012). For instance, traced glucose uptake shows more involvement of carbon from 
glycolysis into lipid construction of macromolecules. Lipid biosynthesis genes are shown 
to be upregulated in TP53 mutant cancer cells that will affect fluidity and lipid saturation of 
plasma membrane (Rysman et al., 2010).  3- affecting tumor environment (Chen et al., 
2007; Chowdhury, Gemin, & Singh, 2005; Comerford et al., 2014; Oldham, Clish, Yang, 
& Loscalzo, 2015). It is fascinating to know that influx seems to be strictly controlled by 
extra matrix stimuli (Grassian, Coloff, & Brugge, 2011). In the absence of growth factors 
or when extracellular matrix is detached, cells did not uptake more glucose and nitrogen 
even with extra nutrients available in the media (Lindsten et al., 2003).  
Unleashed proliferation and invasion of cancer cells requires high import of nutrient 
supply including glucose, glutamine, lipids and fatty acids for cell building block 
construction. Cholesterol inhibition by statins blockade of hydroxymethylglutaryl 
coenzyme A reductase (HMGCR), the rate-limiting step of cholesterol biosynthesis, 
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retained the normal acinar morphology of breast cancer cells (W. A. Freed-Pastor et al., 
2012). Fatty acid enzymes are also reported to be upregulated in multiple cancers.  Fatty 
acid metabolism starts with carboxylation of cytosolic acetyl-CoA carboxylase (AAC) to 
generate malonyl-CoA for further production of long chain fatty acids by fatty acid synthase 
(FASN) (Nomura et al., 2010). Additionally, evidence suggests that cancer cells need 
more glycolysis to escape apoptosis (Hanahan & Weinberg, 2000). In brief, we know net 
influx of carbon, nitrogen and sulfur is increased, but exact metabolites and pathways that 
serve tumor demands are still under investigation. 
 
1.2. P53 AND CELL METABOLISM  
 
p53 is an important tumor-suppressor protein and loss of function of wild type p53 is a 
common event in all human cancers. It is interesting that 75% of p53 mutations are single 
missense mutations that not only lose wild type function but also participate in activities 
that have not been seen in wild-type (P. a J. Muller & Vousden, 2013). The majority of 
these single mutations occur in DNA binding domain that shows the importance of p53 as 
a transcription factor. Yet there are structural mutations that cause conformational 
changes and therefore different function (W. A. Freed-Pastor & Prives, 2012). We can 
divide mutant p53 function into four main groups; 1- binding to DNA to change gene 
expression, 2- binding to transcription factors to promote their function, 3- binding to 
transcription factors to promote their function, 4- interactions with proteins to alter their 
function directly. Mutant p53’s acquired function is vastly context dependent and we 
encounter functions that are inhibitory to another one.  
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Studies of p53 has made it clear that its anticancer activity is far beyond just a 
tumor-suppressor and its connections between p53 and cell metabolism has been 
revealed (Vousden & Ryan, 2009). p53 regulates gene expression of cytochrome c 
oxidase 2 which is crucial in mitochondrial activity. Loss of p53 results in mitochondria 
malfunction and eventually leads to the Warburg effect. TP53-induced glycolysis and 
apoptosis regulator (TIGAR) inhibit glycolysis and upregulate glucose-6-phosphate (G6P) 
for entry into the oxidative arm of the pentose phosphate pathway (PPP) (P. Jiang et al., 
2011). Therefore, ribose and NADDPH will be produced for nucleotide biosynthesis in 
response to DNA damage stress.  Mutant p53 but inactivates the rate-limiting PPP 
enzyme, G6P dehydrogenase to block PPP. Human cell culture deprivation of glucose 
and fatty acids were an indication of the important role of p53 in distributing the energy 
source and regulating gene expression in an attempt to provide an alternative source. For 
example, in case of glucose deprivation, p53 is activated and induces guanidinoacetate 
N-methyltransferase (GAMT) (Ide et al., 2009) and lipin1 (LPIN1) gene expression leading 
to increased fatty acid oxidation (FAO) and fatty acid synthesis inhibition (Assaily et al., 
2011) (Figure 1). p53 upregulation of FAO inhibits glycolysis and this is one of the tumor-
suppressor mechanism of wild type p53. Another important access of p53 to metabolic 
pathways is through binding ability to PGC-1 α. Peroxisome proliferator-activated receptor 
gamma coactivator 1α (PGC-1 α) is a central transcriptional coactivator that strongly 
coordinates lipid metabolic gene expressions (Sen, Satija, & Das, 2011). p53 studies in 
adipocytes of obese mice suggested p53 involvement in fatty acid synthesis such as 
FASN (Yahagi et al., 2003). Mutant p53 interaction with SREBP2 is found to upregulate 
mevalonate pathway gene transcription leading to breast cells acquiring a malignant state 
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(W. A. Freed-Pastor et al., 2012). Additionally, p53 regulates sphingolipids-mediated cell 
cycle and apoptosis (Heffernan-Stroud & Obeid, 2011). 
 
 
 
Figure 1. Graphical overview of p53 and fatty acid metabolism. p53 represses G6PD 
and SREBP and induces LPIN1 and GAMT. Loss of p53 increases anabolism and decreases 
catabolism. Mutant p53 is shown to upregulate SREBP genes. 
 
1.3. RAS SMALL GTPASES 
 
The Ras oncogene family was the first to be discovered and there has been an intense 
effort to inhibit them with targeted pharmaceuticals. Ras proteins are the master regulator 
of cellular signaling and cell cycle, growth, adhesion, migration, and differentiation.  Ras 
is also involved in reprogramming metabolic pathways to support cancer cells’ 
biosynthesis needs. Activated Ras will induce aerobic glycolysis to promote glucose 
import through SLC2A1 stimulation. Ras activation has been linked to elevating non-
hypoxic levels of HIF-1 and MYC activity. SRC phosphorylation is another mechanism of 
controlling glycolytic enzymes by Ras activation.   
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Ras superfamily GTPases includes 21 members of the Rho subfamily, such as 
RhoA, Rac1 and Cdc42, and 18 members of Ras subfamily, such as H-Ras, N-Ras and 
K-Ras. Rho subfamily is known to control actin cytoskeleton, and the Ras subfamily is 
known to control cell growth and is frequently mutated in cancer (Coleman, Marshall, & 
Olson, 2004). Ras/Rho proteins are active when GTP-bound and deactivated when GDP-
bound and a large group of proteins are involved to turn this switch on and off. RasGTP 
and RhoGTP are in a conformational state capable of interacting with other effector 
proteins for initiating downstream signaling cascades.  This tight regulation is achieved by 
guanine nucleotide exchange factors (GEFs) facilitating GDP dissociation and GTP 
binding and GTPase-activating proteins (GAPs) that accelerates Ras/Rho GTP hydrolysis 
to GDP. Rho GDP-dissociation inhibitors (RHOGDIs) regulate Rho proteins by preventing 
nucleotide exchange and membrane association. Although Ras mutation raised 
considerable concern in clinical oncology, Ras oncogenic signaling can be induced by Ras 
deregulation and this has shown to be associated with hyperproliferation (Eckert et al., 
2004). RhoA GTPase is a well-known intercellular regulator in gene expression, cell cycle, 
vesicle trafficking, cell polarity and migration. RhoAGTPase does not get mutated very 
often but cancer progression has been correlated with RhoAGTPase tissue expression to 
the extent that it is suggested as a quantitative marker for staging and prognosis (Sahai & 
Marshall, 2002). 
 
1.4. PRENYLATION 
 
Small GTPases undergo a lipid post-translational modification called prenylation to be 
transferred to the membrane for activation and initiating signaling cascades. Signaling 
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activities of cellular proteins such as Ras, Rac1, and Rab are tightly controlled by 
immobilizing them to a wide variety of subcellular membrane locations. The biological 
function of prenylation is also coming from their role in facilitating protein-protein 
interaction. Prenylation, a side product of cholesterol biosynthesis pathway, is a covalent 
addition of a carbon chain to the carboxyl terminus of proteins contain CAAX sequence. 
Subsequently, the Rce1 endopeptidase cleaves off the three terminal amino acids and the 
prenylated Cys residue is methylated by the isoprenylcysteine carboxyl methyltransferase 
(ICMT).  Farnesylation (15 carbon chain) and Geranylgeranylation (20 carbon chain) both 
referred as prenylation are the products of a 5-carbon building block, 
isopentenylpyrophosphate, from isoprenoid pathway. Genomic and structural and 
functional analysis predicts expression of over two hundred proteins with CAAX sequence 
that undergo prenylation. In conditions where X is a methionine, serine, glutamine or 
cysteine, protein will be farnesylated and where X is a leucine or isoleucine, 
geranylgeranylation is preferred. Prenylation is required for normal cellular function and 
RasGTPases transformation. Ras tends to get farnesylated while Rho is commonly 
geranylgeranylated. Different proteins have different preferences of prenylation, some 
prefer farnesylation, some geranylgeranylation and some can be prenylated either way. 
For example, HRas and NRas are farnesylated whereas KRas can be geranylgeranylated 
if farnesylation is blocked. This phenomenon, known as cross-prenylation, is implicated 
as a cause of resistance to FTIs.   ICMT and RCE1 are able to modify both farnesylated 
and geranylgeranylated proteins but the fact that they are both membrane anchored limits 
their use due to restricted solubility while retaining function ( 
Figure 2).   
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Figure 2. Schematic representation of the prenylation pathway. Compounds used as 
inhibitors of the prenylation are indicated along the pathway. Lona, Lonafarnib; ICMTI, ICMT 
inhibitor; RCE1I, RCE1 inhibitor. 
 
 
1.5. PRENYLATION INHIBITION 
 
Inhibiting HMG-CoA reductase by statins or any of these modifying enzymes, farnesyl-
transferase (FTase) and geranylgeranyl-transferase (GGTase), RCE1 and ICMT have 
been suggested as a cancer therapeutic agent (Walker & Olson, 2005). Statin is a class 
of drugs prescribed for cardiovascular diseases that dramatically reduced the 
cerebrovascular events and mortality. Clinical and epidemiology data for over 20 years 
has suggested a benefit of statin use for cancers patients. Statins are divided into two 
groups of hydrophilic statins (such as pravastatin, rosuvastatin, and fluvastatin) and 
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lipophilic statins (such as atorvastatin, lovastatin, and simvastatin). Statins are considered 
to be safe drugs with few side effects. Researchers have shown the anti-proliferative and 
anti-migrative effect of statins, particularly for lipophilic statins, in vitro followed by mice 
studies in different types of cancer including breast, prostate, gliomas. Epidemiology data 
supports that statin response varies between patients and depends largely on tumor type.   
Zoledronic acid, Nitrogen-contacting Bisphosphonates, bind to farnesyltransferase 
enzyme and therefore inhibits prenylation.  It is the most potent osteoporosis drug being 
used for the clinical adjuvant setting with over 30% breast cancer risk reduction (Drake, 
Clarke, & Khosla, 2008).  Another class of drugs targeting prenylation is FTase inhibitors 
that have been the subject of intense drug development attempt a decade ago in the hope 
of targeting KRAS. FTIs are small molecules that compete with, CAAX motif or FPP to 
bind the FTase.  More than 75 clinical trials for FTase inhibitors (FTIs) have been started 
and among those Lonafarnib and Tipifarnib progressed to phase III (Tsimberidou, 
Chandhasin, & Kurzrock, 2010). Clinical studies demonstrate very low toxicity for 
Farnesyltransferase inhibitors. An alternative prenylation of Ras is geranylgeranylation 
that is shown to be necessary for transformation. Geranylgeranyl transferase inhibitors 
(GGTIs) are developed for Ras targeting. Researchers have reported successful results 
in vitro and in animal models (Kazi et al., 2009; Sun, Ohkanda, Coppola, Yin, Kothare, 
Busciglio, & Hamilton, 2003; Zimonjic et al., 2013). Selective GGTIs have demonstrated 
to impede transformation and tumor development in vivo (Peterson, Kelly, Weinbaum, & 
Casey, 2006; Sun, Ohkanda, Coppola, Yin, Kothare, Busciglio, Hamilton, et al., 2003; 
Vogt, Sun, Qian, Hamilton, & Sebti, 1997). GGTIs increase apoptosis and cell cycle arrest 
in G1 which is not observed for FTIs (Drake et al., 2008; Sun et al., 1999). There are 
ongoing clinical trials for different GGTIs for example GGTI-2148 for breast cancer and 
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myeloma that is going to start for phase I/II. RCE1 and ICMT inhibitors are another group 
of drugs for targeting Ras oncogenic signaling by prenylation inhibition. It has been shown 
that knocking down RCE1 protease or methyltransferase leads to RAS mislocalization 
(Bergo et al., 2000; Kim et al., 1999). It is striking that ICMT gene disruption completely 
shut down the KRAS-mediated transformation of fibroblasts and BRAF oncogenic 
transformation (Bergo et al., 2004). Unfortunately RCE1 and ICMT inhibitors are not 
meeting the required safety profile yet to enter the clinical setting (Winter-Vann & Casey, 
2005).  
 
 
1.6. THERAPEUTIC METHODS FOR P53 DEFICIENCY IN TUMOR 
 
p53 function is so critical for cancer prevention that p53 loss of function is the most 
common cancer cells event. There is no doubt that developing therapies for preserving 
p53 function will do a great service to cancer field. Inhibition of p53-MDM2 interaction is 
one of the strategies that has been applied to prevent inhibitory effect of MDM2. Nutlin3 
is a potent drug that competes with MDM2’s binding domain enhancing wild-type p53 
dependent apoptosis in cancer cells (Grasberger et al., 2005; Issaeva et al., 2004; 
Vassilev, 2004). Targeting mutant p53 is another important option that has made 
considerable progress. PRIMA-1 is a good example that specifically targets growth of 
mutant p53 and has made it to phase I clinical trial (Bykov et al., 2002).  17AAG is an 
HSP90 inhibitor that disrupt HSP90-mp53 complex hence sends mp53 off to degradation 
(Li et al., 2011). Lastly, p53 vaccines have been designed stimulating an immune 
response to p53. Wild-type p53 has a short half-life in comparison with mutant p53 in 
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cancer cells. Studies have shown p53 antibodies in cancer patients’ sera suggesting that 
p53 antigen could be used for immunotherapy (Katchman et al., 2016). One of the 
methods that is extensively developing is gene therapy for delivering wild type p53 to 
cancer cells. Adenoviral delivery of p53 increases apoptosis and prevent tumor 
progression in different in vitro and in vivo studies of neck cancer (Clayman et al., 1995), 
lung cancer (Zhang et al., 1994), prostate cancer (C. Yang, Passaniti, Cirielli, Capogrossi, 
& Cirielli, 1995). The same method of gene therapy can be used to directly deliver other 
p53 family proteins such as p63 and p73 that can do p53 function (Bisso, Collavin, & Del 
Sal, 2011; Jost, Marin, & Kaelin, 1997). Genetic editing advancements by discovery of 
CRISPR-Cas9 technology has opened new avenues to the field of gene therapy. CRISPR-
Ca9 system raises the hope to correct genetic diseases including Li-Fraumeni syndrome 
which is caused by TP53 loss of function and over 80% TP53 missense mutation.  In 
addition, this dissertation introduces a modulated Cas9 for a more efficient and immune 
silent CRISPR-Cas9 gene therapy.  
 
1.7. THESIS CONTRIBUTIONS 
 
This dissertation addresses a number of fundamental gaps in understanding the 
mechanism of p53 mutation gain of function in cancer. The mevalonate pathway regulation 
in mutant p53 tumors with the focus on signaling events. The primary contributions of this 
dissertation to the field of cancer biology are: 
1. Detailing the impact of p53 mutations dependence on proliferation and 
migration. 
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2. Demonstrating that the oncogenic mutant p53/Ras/RhoA pathway is 
activated by p53.  
1. Systematic analysis of the correlation of prenylation inhibition, including 
FTI, GTI, and statins, with 4 different TP53 mutations in breast cancer cell 
lines. 
2. Discovery of an inhibitory mechanism of statin on mutant p53 proliferation 
and migration. 
3. Biochemical analysis, including co-IP and immunofluorescence, to 
demonstrate that simvastatin functions in the context of mutant p53 to block 
Ras- induced-RhoA activation. 
4. Identifying a gene signature, termed MPR (mutant p53-Ras) that 
combines expression of 17 genes within the Ras pathway with TP53 
mutation status to predict anti-tumor response to statin inhibition.   
5. Prediction of the frequency of potential “statin-sensitive” breast cancers 
within the TCGA cohort.  
In addition to clarifying the role of Ras and RhoA activation in mutant p53 cells, 
this dissertation also describes the development of a method to improve gene therapy with 
CRISPR-Cas9 system relevant to targeting p53 loss of function: 
1. Identification of pre-existing T cell and B cell immune response to Cas9 
protein in human. 
2. Identification of the two immunodominant T cell epitopes of Cas9 protein.  
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CHAPTER 2 
PRENYLATION INHIBITION IN MUTANT P53 CELLS 
2.1. ABSTRACT 
 
TP53 driver mutations are independent biomarkers of poor prognosis in 
adenocarcinomas. Despite the difficulty in developing direct inhibitors of mutant p53 
(mp53), identification of pathways that confer synthetic lethality with mp53 may reveal 
therapeutic strategies. In this study, we highlight the downstream effect of the mevalonate 
pathway on prenylation, that is necessary for mp53-induced activation of proliferation and 
migration. We show that inhibiting prenylation in vitro by statins blocks farnesylation and 
geranylgeranylation of Ras and Rho induced by mp53. Select TP53 mutations increase  
the sensitivity to prenylation inhibitors in stably transduced MCF10A cell lines. 
Transcriptome analysis of MCF10A cells expressing mutant and wild-type p53 
demonstrates that the Ras/Rho small GTPases are upregulated in cells expressing mp53, 
and the FoxO signaling apoptotic pathway is induced post-statin treatment (p<0.024, Fold 
enrichment≃1.84). We defined a mp53/Ras (MPR) gene expression signature (composed 
of 16 genes and TP53 mutation status) to predict response to statins. This gene signature 
was validated in two cell line datasets, 17 breast cancer cell lines (89% accuracy), and the 
NCI-60 cell line panel (100% accuracy). In summary, we have identified Ras and RhoA 
as key downstream mediators of p53 mutation, and have used these data to build and 
validate a predictive classifier of prenylation inhibition. 
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2.2. BACKGROUND 
 
TP53 is the most common driver mutation in human cancers, but targeted inhibitors have 
been elusive (W. A. Freed-Pastor & Prives, 2012; P. a J. Muller & Vousden, 2013). In 
addition to genetic instability due to loss of wild type p53, there is a wide spectrum of 
neomorphic functions of mutant p53 that alter downstream pathways to enhance tumor 
progression, survival, and migration. Synthetic lethal targeting of these perturbed cellular 
pathways that mediate mutant p53 gain of function results in reducing p53 mutation 
oncogenesis (Khoo, Hoe, Verma, & Lane, 2014; P. A. J. Muller & Vousden, 2014; Parrales 
& Iwakuma, 2015; Wade, Li, & Wahl, 2013; Yu, Narayanan, Vazquez, & Carpizo, 2014). 
The mevalonate pathway is one of the pathways upregulated in mutant p53 breast cancer 
cell lines and inhibiting this pathway by statins has resulted in inhibition of malignant 
phenotypes (Clendening et al., 2010; W. A. Freed-Pastor et al., 2012; W. Freed-Pastor & 
Prives, 2016). One product of the mevalonate pathway is protein prenylation, which is 
necessary for Ras and Rho translocation to the cell membrane for activation and initiation 
of downstream signaling (Berndt, Hamilton, & Sebti, 2011; M. Wang & Casey, 2016).  
It is not surprising that cooperation between two cancer drivers, mutant p53 and 
Ras signaling pathway, expedites transformation. Mutations in TP53 usually occur in the 
absence of Ras mutation, but Ras overexpression can trigger similar oncogenic signaling 
mechanisms as mutations in Ras, and is associated with uncontrolled proliferation (Eckert 
et al., 2004). Loss of p53 increases Ras activity and aberrant Ras activation, result in p53-
mediated apoptosis (Ma, Magut, Chen, & Chen, 2002; Xia & Land, 2007). However, Ras 
has a complex dynamic interaction with RhoA, leading to RhoGTPase-mediated 
downstream signaling. RhoGTPases are reported to be upregulated in the presence of 
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p53 mutation promoting YAP/TAZ activation that can be controlled by inhibiting the 
mevalonate pathway (Sorrentino et al., 2014). RhoGTPases are both upstream and 
downstream activators of PI3K leading to cell polarization and recruitment of PI3K to the 
plasma membrane for cell migration (Fritsch et al., 2013; H. W. Yang et al., 2012). 
Activation of Rac1 and Cdc42 and mitogenic kinase signaling is required for Ras-induced 
transformation (Khosravi-far et al., 1995). The mechanisms of how the Ras and Rho 
signaling pathways integrate to contribute to oncogenesis in mutant p53 tumors is under 
active investigation (Lawson et al., 2016). 
Farnesylation and geranylgeranylation are the products of a 5-carbon building 
block, isopentenylpyrophosphate, derived from the mevalonate pathway and both are 
required for normal cellular function and RasGTPase-mediated cellular transformation 
(Berndt et al., 2011; M. Wang & Casey, 2016). Inhibition of HMG-CoA reductase, the rate-
limiting step of the mevalonate pathway, by statins, or inhibition of any of the prenylation 
enzymes, such as farnesyl-transferase (FTase), geranylgeranyl-transferase (GGTase), 
Ras Converting CAAX Endopeptidase 1 (RCE1),  or isoprenylcysteine carboxyl 
methyltransferase (ICMT) are under investigation as cancer therapeutics (Walker & Olson, 
2005). The anticancer effect of statins, especially hydrophobic statins such as simvastatin, 
has been observed in multiple clinical studies (Coxon, Oades, Kirby, & Colston, 2004; Xie, 
Li, Gong, Zhang, & Ma, 2015). The use of cholesterol-lowering medication during adjuvant 
endocrine therapy is associated with lower breast cancer recurrence in hormone receptor–
positive early-stage breast cancer in a retrospective study (Borgquist et al., 2017). Statin 
use has also been associated both with lower cancer incidence and improved recurrence-
free and overall survival, leading to ongoing clinical trials (Bjarnadottir et al., 2013; Brewer 
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et al., 2013; Nielsen, Nordestgaard, & Bojesen, 2012; “Postdiagnosis Statin Use and 
Mortality in Danish Patients With Prostate Cancer.,” n.d.).   
Here, we hypothesized that the neomorphic activity of mutant p53 functions, in 
part, by increased prenylation of Ras and RhoA, both of which can be blocked by inhibitors 
of the mevalonate pathway. Using a panel of MCF10A cell lines engineered to express 
different mutant p53 proteins as well as breast cancer cell lines, we demonstrate that the 
activation of Ras and RhoA signaling can be readily blocked by inhibitors of the 
mevalonate pathway, including by statins.  We developed a combined genomic and 
transcriptomic signature to predict response to prenylation inhibitors, such as statins. This 
study highlights the importance of prenylation inhibition in the setting of tumors harboring 
somatic mutations in TP53.  
 
 
2.3. MATERIAL AND METHODS 
 
2.3.1. Cell lines and culture conditions 
 
All human breast cancer cell lines were obtained from American Type Culture Collection 
(ATCC, Manassas, VA) and maintained at 37°C and 5% CO2. For MDA-MB-231, MCF-7, 
and MDA-MB468, DMEM and for HCC70, SKBR3 and TD47, RPMI supplemented with 
10% fetal bovine serum (FBS) was used. MCF10A cells were maintained in DMEM/F12 
supplemented with 5% horse serum, 10 μg/ml insulin, 0.5 μg/ml hydrocortisone and 
20 ng/ml epidermal growth factor (EGF). All cell culture chemicals were obtained from 
Invitrogen (Carlsbad, CA). Mycoplasma contamination was monitored periodically. 
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2.3.1. Chemicals, antibodies, and reagents 
 
The anti-GAPDH mAb was obtained from Sigma (St. Louis, MO). Raf-1 antibody (#20446) 
was obtained from Santa Cruz Biotechnology (Dallas, TX) and Ras antibody (#MA1-012X) 
from Thermo Fisher Scientific was used for imaging. Anti-RhoA mAb (#ARH03), anti-Pan 
Ras mAb (#AESA02) from Cytoskeleton (Denver, CO) were used for RhoAGTP and 
RasGTP pull-down assays. Simvastatin (#6196), cholesterol (#C8667), farnesyl 
pyrophosphate (FPP) (#F6892), geranylgeranyl pyrophosphate (GGPP) (#76532), 
geranylgeranyltransferase inhibitor (GGTI-2133) (#G5294) and zoledronic acid 
monohydrate (#SML0223) were obtained from Sigma. Purified (>99%) simvastatin was 
dissolved into refrigerated and light-protected DMSO stock solutions and stored at -20 °C 
in 10 mM aliquots. Lonafarnib (Toronto Research Chemicals, ON, Canada), 
isoprenylcysteine carboxyl methyltransferase (ICMT) inhibitor (EMD Millipore, Temecula, 
CA) and farnesyl protein transferase inhibitor (EMD Millipore) were stored at -80°C in 5mM 
aliquots according to the manufacturer’s instructions.   
 
2.3.3 Cell proliferation and apoptosis assays  
 
To quantitate in vitro cell proliferation, 2×105 cells/mL of cells were seeded in a 96-well 
plate in triplicate and treated for 24 hours with 0- 20 µM doses of drug, and cell viability 
was determined at 48-96 hrs using the CellTiter-Glo® luminescent cell viability assay 
(Promega, Fitchburg, WI). Apoptosis was measured by Caspase-Glo® 3/7 Assay 
(Promega). Dose response curves were produced to determine the specific IC50 values. 
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2.3.4. Immunoblot analysis 
 
Briefly, 2-5×106 cells were harvested by manual dissociation with ice-cold PBS, 
and resuspended in 300µl RIPA buffer (Invitrogen) containing a cocktail of protease 
inhibitors (Roche Diagnostics, Indianapolis, IN). Total protein concentration was 
measured by Pierce BCA assay from Thermo Fisher Scientific. Equal amounts of protein 
were loaded on a 4-20 % SDS–poly-acrylamide gel and transferred to a polyvinylidene 
fluoride membrane. The membrane was incubated with 5% nonfat dry milk in PBST for 1 
hr at rt. Primary Ab was added as recommended dilutions and bound Ab detected with 
ECL substrate (BioRad, Hercules, CA).  
 
2.3.5. Immunoprecipitation 
 
Ras and RhoA activity was measured using a Ras pull-down activation assay 
(Cytoskeleton). Ten million cells were lysed with the provided lysis buffer and equal 
amounts of cell extracts were incubated with GST-tagged Raf1-RBD (Ras binding domain) 
or Rhotekin-RBD (Rho binding domain) for an hour. Raf1-RBD/Ras-GTP or RhoAGTP 
was successfully pulled down using glutathione affinity beads that was provided by the 
company. Immunoblot with provided anti-Ras and anti-RhoA antibodies were used to 
measure the quantity of the pulled down protein.  
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2.3.6. Quantitative real time-PCR 
 
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Germantown, MD) according per 
the manufacturer's instructions. The A260/A280 ratio and RNA concentration were 
determined using a NanoDrop. The RNA integrity was determined by microfluidic capillary 
electrophoresis using an Agilent 2100 Bioanalyzer and the RNA 6000 Nano Chip kit 
(Agilent Technologies, Santa Clara, CA). Primers were designed by Primerquest and 
obtained from IDT (Integrated DNA Technologies, Coralville, Iowa). Number of genes from 
RNA-Seq results were validated by quantitative real-time-PCR (qRT-PCR) on Applied 
Biosystems Vii7 (Life Technologies). cDNA was synthesized using iScript cDNA Synthesis 
kit (BioRad) with oligo(dT) in a (BioRad T100) thermocycler (5 minutes at 25°C; 30 minutes 
at 42°C; 5 minutes at 85°C). Expression levels were relative to GAPDH expression using 
2−ΔΔCt analysis method. Experiments were done at least twice with three replicates.  
 
2.3.7. RNA-Seq  
 
RNA was used to prepare cDNA using Nugen’s Ovation RNA-Seq System via 
single primer isothermal amplification (Catalogue #7102-A01) and automated on the 
(Apollo 324 liquid handler from Wafergen). cDNA was quantified on the Nanodrop 
(Thermo Fisher Scientific) and was sheared to approximately 300 bp fragments using the 
Covaris M220 ultrasonicator. Libraries were generated using Kapa Biosystem’s library 
preparation kit (KK8201). Fragments are end-repaired and A-tailed, individual indexes and 
adapters (Bioo, catalogue #520999) are ligated on each separate sample. The adapter 
ligated molecules were cleaned using AMPure beads (Agencourt Bioscience/Beckman 
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Coulter, A63883), and amplified with Kapa’s HIFI enzyme (KK2502). Each library was then 
analyzed for fragment size on an Agilent’s Tapestation, and quantified by qPCR (KAPA 
Library Quantification Kit, KK4835) on Thermo Fisher Scientific’s Quantstudio 5 before 
multiplex pooling and sequencing a 1x50 flow cell on the HiSeq2000 platform (Illumina) at 
the ASU’s Genomics Core facility. Sequence reads will be deposited in the NCBI 
BioSample database. RNA-Seq reads for each sample were quality checked using 
FastQC v0.10.1 and aligned to the human genome build 38 (GRCh38) primary assembly 
from Ensembl Database using STAR v2.5.1b. A series of quality control metrics were 
generated on the STAR outputs. Cufflinks v2.2.1 was used to report FPKM values 
(Fragments Per Kilobase of transcript per Million mapped reads) and read counts. 
Differential expression (DE) analysis was performed with EdgeR package from 
Bioconductor v3.2 in R 3.2.3. Multi-dimensional scaling (MSD) plot was drawn by 
plotMDS, in which distances correspond to leading log-fold-changes between samples. 
For each comparison, genes with false discovery rate (FDR) <0.05 were considered 
significant and log2-fold changes of expression between conditions (logFC) were reported. 
Pathway enrichment was performed by DAVID 6.7 Functional Annotation Tool 
(https://david.ncifcrf.gov/). Genes enriched in Go terms, KEGG pathways, Panther 
pathways and Reactome pathways were reported. 
 
2.3.8. Statistical analysis 
 
Data are presented as mean ± SD. The number of replicates for each experiment is stated 
in the description. Statistical differences between and among groups were determined by 
two-tailed t test and one-way ANOVA followed by Tukey’s range test, respectively. IC50 
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value is determined by GraphPad using log(inhibitor) vs. drug response equation with four 
parameters. The statistical significance of Kaplan–Meier survival plot was determined by 
log-rank analysis. Statistical analysis was performed by Microsoft Excel 2013 and 
GraphPad Prism 6.0 and R version 3.4.0, unless mentioned otherwise in the figure 
legend.  
 
 
2.3.8. Gene signature analysis 
 
From a list of genes (310 genes) from small GTPase-mediated signal transduction 
pathways, 46 genes were differentially expressed in at least two mp53.MCF10As cell 
lines, pre-statin treatment. Hierarchical clustering of the Log2(FPKM) of these 46 genes 
for mp53 and wtp53.MCF10A is shown in a heatmap (Figure 15). In order to construct a 
classifier with Ras signature to predict simvastatin response, IC50 values =20 was used as 
cutoff to separate 17 cell lines into two categories: resistance and sensitive during training.  
A Random Forest classifier is trained on the basal gene expression with two categories 
as the response variable. Variable importance provided by the Random Forest is then 
used to select a smaller subset of probes that are highly predictive of SV response (34 
probes). Then probes with small variance among all cell lines were filtered out (32 probes). 
Finally, probes with high Pearson-correlation coefficient between the gene expression 
level and sensitivity were selected (16 probes). The final mP53-Ras (MPR) gene signature 
for SV response consists of RNA expression of 16 genes and mutation status of TP53. 
The statin response classifier was constructed by gradient boosting method. All the 
analysis was performed in Python Anaconda platform.    
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2.4. RESULTS 
 
2.4.1. Prenylation inhibitors reverse malignant phenotypes  
 
To study the impact of TP53 mutation on prenylation, non-malignant mammary MCF10A 
cells were stably transduced to overexpress ten of the most common missense mutations 
of TP53 (W. A. Freed-Pastor & Prives, 2012) and overexpressed (OE) wild-type p53 was 
used as a control. These cell lines are referred to here as mp53.MCF10A and 
wtp53.MCF10A, respectively.  The expression of mutant p53 was confirmed by 
immunoblot in comparison to wtp53.MCF10A (OE), empty vector transduced MCF10a 
cells (EV.MCF10A), and 5 cancer cell lines with known p53 mutations  (Figure 3). 
 
 
 
Figure 3. Mutant p53 expression level in the generated MCF10As. Immunoblot 
representing protein expression of mp53 in comparison to GAPDH as the control. WT OE: 
wtp53.MCF10A, WT EV: empty vector transduced MCF10a cells. 
 
To investigate the effect of prenylation inhibition on the proliferation of four mutant 
p53 cells, we selected a panel of prenylation inhibitors, each blocking a different stage of 
the pathway (Table 1). Simvastatin (SV), a competitive inhibitor of HMG-CoA reductase, 
was used to inhibit upstream mevalonate production. Zoledronate, a bisphosphonate that 
inhibits farnesylpyrophosphate synthase, blocks both farnesylation and 
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geranylgeranylation. Lonafarnib selectively inhibits farnesylation, and GGTI-2133 
selectively inhibits geranylgeranylation (Berndt et al., 2011; Thurnher, Nussbaumer, & 
Gruenbacher, 2012).  RCE1 is a protease that cleaves three c-terminal residues of both 
farnesylated and geranylated proteins. NSC1008 was used as a selective  RCE1 inhibitor 
(Mohammed et al., 2016). The final step of prenylation is the methyl esterification of the α 
carboxyl group of prenylcysteine, and is blocked by  ICMT inhibitor II-FTPAT (Bergo et al., 
2004).  
 
Table 1. The half maximal inhibitory concentration of prenylation 
inhibitors for the generated MCF10As. 
 
 
 
As shown in Table 1, proliferation in all four mp53.MCF10A cell lines is decreased 
after 48 hours of drug treatment in comparison to the wtp53.MCF10A.  To compare the 
specificity of these drugs to target cells expressing mutant p53, the ratio of the average of 
the IC50 value of the four mp53.MCF10A cell lines over the IC50 value of wild-type is 
shown as wt-IC50 / mut-IC50.  Of all inhibitors, simvastatin had the greatest overall 
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specificity for mutant p53, with an IC50 ratio of 2.7.  However, there was a range of 
sensitivity to simvastatin, with R273H and G245S twice as sensitive as R248Q and 
Y234C. 
To further evaluate the impact of p53 mutation on sensitivity to simvastatin, we 
measured proliferation of 10 mp53.MCF10A cell lines after 60 hours of SV treatment 
(Figure 4). We confirmed that MCF10A cells expressing the p53 mutations R248Q and 
Y234C were relatively resistant to SV compared to 8 other p53 mutations, which did not 
correlate with the level of mutant p53 protein expression (Figure 4).   
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Figure 4. Simvastatin proliferation inhibition of mutant p53 MCF10As. Proliferation 
percent of mp53 MCF10A cells is reported for 5µM SV-treated cells vs vehicle-treated cells 
after 60 hrs. 
 
The most sensitive mutation was G245S, which is in the DNA binding domain, but 
there was no clear correlation between SV sensitivity and presence of mutation in the DNA 
binding domain or the mutations that alter protein conformation (W. A. Freed-Pastor & 
Prives, 2012) (Figure 5). There are mutations that are in DNA binding domain but shown 
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to change to conformation therefore grouped as conformational mutation. It is apparent 
that wild-type over-expressed p53 (OE) as the control is less sensitive to all the mutations 
A 
 
B 
 
Figure 5. Dose-response to simvastatin in mutant p53 MCF10A. (A) DNA contact 
mutations of p53. (B) conformational mutations of p53 
 
 
 Inhibition of proliferation by SV is associated with induction of apoptosis in p53 
R273H.MCF10A cells (Figure 6). Same doses of concentration are used to compare the 
both assays. This experiment is designed to test whether the cell viability decreases due 
to only senescence, or apoptosis as an anticancer activity is involved.  
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Figure 6. Correlation of proliferation inhibition with apoptosis induction in mutant 
p53 MCF10A. Proliferation inhibition (CellTiter-Glo assay) and apoptosis induction (Caspase-Glo 
3/7 assay) is reported for various SV doses (5, 10, 15, 20, 25, 30) after 48 hrs as a percentage of 
control. 
 
Unlike the targeted prenylation inhibitors in Figure 2, simvastatin has other effects 
on cholesterol inhibition. To determine whether proliferation inhibition is the direct result 
of prenylation inhibition, SV-treated (24 hrs, 5µM) wtp53.MCF10A and mp53.MCF10A cell 
lines were cultured with cholesterol, farnesyl pyrophosphate (FPP), or geranylgeranyl 
pyrophosphate (GGPP) to rescue inhibition. Both FPP and GGPP, but not cholesterol, 
efficiently rescued proliferation (Figure 7). FPP is the intermediate product necessary for 
farnesylation. GGPP is the intermediate product in the mevalonate pathway required for 
geranylgeranylation. The fact that either FPP or GPP are capable of rescuing the cell 
proliferation means that they can be alternatively used. This effect was no different for 
R248Q mutation that shows less sensitivity to simvastatin. Same concentration of FPP or 
GPP was enough independent of how much the proliferation was inhibited. 
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Figure 7. Rescue experiment for simvastatin treatment of mutant p53 MCF10A. 
GGPP and FPP rescued the viability of SV-sensitive mp53.MCF10As. wtp53.MCF10A and 
p53R248Q, p53G45S, and p53R273H.MCF10A were treated with 5 µM SV (for 48 h) and vehicle.  
5 µM Cholesterol, GGPP, and FPP were added after 24 hrs. 
 
To determine whether prenylation inhibition reverses mutp53-induced cell 
migration, we preformed wound healing assays with the wtp53.MCF10A and 
mp53.MCF10A cell lines. Prenylation inhibition reduced migration in all cell lines, but a 
greater effect was observed in the highly migratory G245S, R273H, and Y234C cell lines 
(Figure 9). The inhibition of migration of p53R273H.MCF10A cells after 24 and 48 hours of 
SV or GGTI-2133 treatment is shown in Figure 8.  
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Figure 8. Migration inhibition assay of mutant and wild type p53 MCF10A. Scratch 
assay for p53R273H.MCF10A and WT-OE after 24 and 48 hrs of SV treatment and GGTI-2133 with 
vehicle-control. Simvastatin=SV, GGPP=Geranylgeranyl pyrophosphate, FPP= farnesyl 
pyrophosphate 
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Figure 9. Migration inhibition by prenylation inhibitors for 5 different mp53.MCF10A 
cell lines is compared to wtp53.MCF10A using a wound healing assay after 24 hrs. 
Concentrations are 500 nM for GGTI-2133 and Lonafarnib, and ICMTI; 5µM simvastatin; and 
25µM zoledronic acid. 
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2.4.2. mp53 recruits Ras superfamily GTPases for aberrant cell signaling. 
 
To determine the mechanism of SV activity, we performed RNA-Seq analysis of 
mp53.MCF10A (p53Y220C, p53R248Q, p53R273H, p53G245S. MCF10A) and wtp53.MCF10A cells 
before and after SV treatment. Vehicle treatment (0.1% DMSO) was used for measuring 
baseline mRNA expression. Since gene expression is an early event we used a low SV 
concentration (2.5 µM) that preserves morphology and limits senescence. The global gene 
expression pattern between wild-type and mutant p53 and between SV-treated (red) and 
vehicle-treated (black) cells is shown by Multi-dimensional scaling (MSD) (Figure 10). The 
MSD plot indicates that each cell line exhibits distinct separation between themselves, 
and the SV-sensitive cell lines (p53R273Hand p53G245S.MCF10A) have the highest similarity 
prior to SV treatment.  
 
 
Figure 10. Multi-dimensional scaling plot. Multi-dimensional scaling of logarithm of the 
gene expression fold change shows the SV sensitive mutant p53s are clustered distinctly. 
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We performed genes enrichment analysis of differentially expressed genes between 
mp53.MCF10As vs. wtp53.MCF10A using the DAVID pathway analysis tool. it is evident 
that signal attenuation is an important, common enriched pathway caused by the p53 
mutation (Table 1 and Appendix A). There is a strong body of knowledge on p53 mutation 
gain of function on changing the generic transcription (W. A. Freed-Pastor & Prives, 2012) 
but less attention has been paid to the signaling events. Enriched pathways like ErbB 
signaling, Ras signaling, RhoGTPase cycle, PI3K and MAPK signaling are closely related 
to development, proliferation, and migration. To break down the function of the enriched 
pathways, Cytoscape biological function tool was applied to the most differentially 
expressed genes in p53R273H.MCF10As vs. wild-type (P<0.05) (Figure 11). The 
interactome model is presented, comprised of 10 functionally discrete sub-networks or 
modules including “small GTPase-mediated signal transduction” and “Transmembrane 
receptor protein tyrosine kinase signaling pathway” (RTK) that are highly interconnected 
to “Positive regulation of developmental growth”, “Epithelial cell migration”, and “Cellular 
response to fibroblast growth factor stimulus” (Figure 11). 
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Figure 11. Biological function analysis of mutant p53R273H MCF10A. Global overview 
of biological functions of enriched pathways in p53R273H.MCF10A vs wtp53.MCF10A using 
Cytoscape. Pathways within the same biological function are sized and colored the same and 
corresponding to their p-values.  
 
Next, we applied the DAVID pathway analysis tool to identify the most targeted 
pathways post-SV treatment in mp53.MCF10As and wtp53.MCF10A  
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Table 2. Pathway analysis for p53R273H.MCF10A. Gene Ontology (GO) enrichment 
analysis using DAVID for differentially expressed genes in mp53.MCF10A cell lines vs 
wtp53.MCF10A identifies pathways that are implicated in mutant p53 gain of function in cancer. 
 
Category Term P-Value FE 
KEGG hsa04142: Lysosome 8.15E-05 2.23 
KEGG hsa04010: MAPK signaling pathway 2.08E-04 1.74 
REACTOME hsa983168: Antigen processing: Ubiquitination & Proteasome degradation 5.53E-04 1.66 
KEGG hsa04015: Rap1 signaling pathway 7.73E-04 1.75 
REACTOME R-HSA-5621575: CD209 (DC-SIGN) signaling 0.0010 3.97 
KEGG hsa04012: ErbB signaling pathway 0.0012 2.22 
KEGG hsa04664: Fc epsilon RI signaling pathway 0.0012 2.41 
REACTOME R-HSA-112409: CD209 (DC-SIGN) signaling 0.0014 4.98 
KEGG hsa01100: Metabolic pathways 0.0020 1.23 
KEGG hsa04066: HIF-1 signaling pathway 0.0021 2.07 
KEGG hsa05219: Bladder cancer 0.0023 2.82 
KEGG hsa04668: TNF signaling pathway 0.0025 2.00 
KEGG hsa04722: Neurotrophin signaling pathway 0.0025 1.93 
REACTOME R-HSA-4419969: Depolymerisation of the Nuclear Lamina 0.0033 4.32 
REACTOME R-HSA-2562578: Depolymerisation of the Nuclear Lamina 0.0038 5.05 
KEGG hsa04912: GnRH signaling pathway 0.0049 2.02 
KEGG hsa04070: Phosphatidylinositol signaling system 0.0050 1.97 
KEGG hsa00562: Inositol phosphate metabolism 0.0053 2.17 
REACTOME R-HSA-194840: Rho GTPase cycle 0.0053 1.82 
REACTOME R-HSA-381038: XBP1(S) activates chaperone genes 0.0057 2.31 
KEGG hsa05205: Proteoglycans in cancer 0.0078 1.59 
KEGG hsa04370: VEGF signaling pathway 0.0084 2.21 
KEGG hsa04014: Ras signaling pathway 0.0093 1.54 
KEGG hsa05221: Acute myeloid leukemia 0.011 2.24 
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KEGG hsa04510: Focal adhesion 0.012 1.55 
KEGG hsa04962: Vasopressin-regulated water reabsorption 0.013 2.41 
REACTOME R-HSA-204174: Regulation of pyruvate dehydrogenase (PDH) complex 0.013 3.97 
KEGG hsa04064: NF-kappa B signaling pathway 0.016 1.89 
REACTOME R-HSA-6807878: COPI-mediated anterograde transport 0.016 1.79 
KEGG hsa05215: Prostate cancer 0.017 1.86 
REACTOME R-HSA-140534: Ligand-dependent caspase activation 0.017 3.70 
KEGG hsa04925: Aldosterone synthesis and secretion 0.018 1.91 
REACTOME R-HSA-5684264: MAP3K8 (TPL2)-dependent MAPK1/3 activation 0.023 3.47 
KEGG hsa04620: Toll-like receptor signaling pathway 0.023 1.73 
REACTOME R-HSA-200425: Import of palmitoyl-CoA into the mitochondrial matrix 0.024 4.21 
KEGG hsa05200: Pathways in cancer 0.025 1.33 
KEGG hsa04611: Platelet activation 0.025 1.63 
REACTOME R-HSA-1660499: Synthesis of PIPs at the plasma membrane 0.025 2.45 
REACTOME R-HSA-375165: NCAM signaling for neurite out-growth 0.026 2.94 
REACTOME R-HSA-2024096: HS-GAG degradation 0.026 2.94 
KEGG hsa04380: Osteoclast differentiation 0.027 1.62 
KEGG hsa05231: Choline metabolism in cancer 0.029 1.72 
REACTOME R-HSA-937072: TRAF6 mediated induction of TAK1 complex 0.030 3.27 
REACTOME R-HSA-2032785: YAP1- and WWTR1 (TAZ)-stimulated gene expression 0.031 2.55 
KEGG hsa05220: Chronic myeloid leukemia 0.032 1.88 
KEGG hsa00511: Other glycan degradation 0.032 3.22 
KEGG hsa05212: Pancreatic cancer 0.033 1.93 
REACTOME R-HSA-2559585: Oncogene Induced Senescence 0.037 2.47 
 
 
For p53R273H.MCF10A, these pathways are broadly summarized as HMG-CoA reductase 
related pathways (mevalonate pathway), response to damage, apoptosis, transcription, 
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and signaling pathways (Figure 12). It is critical to seek further biological validations for 
founded conclusions from gene expression data analysis rather than solely rely on the p-
values. 
 
 
 
 
Figure 12. Pathway analysis for statin p53R273H.MCF10A. Enriched pathways in 
p53R273H.MCF10A SV treated vs vehicle-control. Orange bars are Cholesterol related pathways. 
DAVID is used for gene enrichment analysis as described in the method section. 
 
First, using quantitative-reverse transcriptase PCR (RT-qPCR), we validated 
HMGCR expression dose-dependent increase upon SV treatment (Figure 13). Inhibiting 
HMGCR activates the feedback loop to transcribe more enzyme in order to compensate 
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for the deactivated enzyme. We used 10 and 20 µM to get a clear difference in gene 
expression. Statin range of concentration that is commonly applied for pre-clinical studies 
varies between 0-20 µM. The physiological range of statin in patient sera is about 3 µM 
and definitely not more than 5 µM. 
 
 
Figure 13. HMGCR expression is upregulated after cholesterol biosynthesis 
pathway inhibition. In consistent with RNA-Seq results for mp53.MCF10A cell lines, after 2.5 µM 
SV treatment HMGCR is significantly upregulated as a result of the feedback loop. Dose 
dependency is demonstrated for p53R248Q and p53R273H.MCF10As. 
 
Then assessed the expression of the key transcriptional genes involved in the 
mevalonate pathway including SREBP2, SREBP1c and LDLR (Figure 14). There was a 
significant upregulation of these genes under cholesterol-deprived conditions. Therefore, 
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the mevalonate pathway feedback loop is completely functional regardless of TP53 status 
and there is another underlying mechanism for cell sensitivity to statin treatment. That  
 
 
 
 
Figure 14. Cholesterol deprivation resulted in significant upregulation of low 
density lipoprotein receptor (LDLR) expression in mp53.MCF10A cells in compare to the 
wild-type. Expression of Sterol Regulatory Element Binding Protein 1c and 2 (SREBP1c, 
SREBP2) and LDLR as genes involved in the cholesterol pathway feed-back loop are measured 
using RT-qPCR in the following condition. NT cells are in regular standard serum containing 
media. Cells were incubated in media with Lipoprotein deficient serum for 24 hrs with and without 
30µg/ml cholesterol. 
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motivated us to validate a panel of 17 genes critical in small GTPases and RTK signaling 
pathway from our RNA-Seq data that had a significant differential expression in mp53 cells 
vs wtp53 (Figure 15). Upregulation of Ras and RhoGTPases and GTPase activators 
(AGAP4, AGAP6, ARGHGAP28, ACAP3, DLC1, SYDE1, PLEKHG6, RAPGEF), growth 
factor signaling genes (ERBB2, PTK2 and GRB2,) and downregulation of Rho activation 
inhibitors (ARGHDIB, ARHGDIA) and anti-proliferation gene (BTG2) in mp53 cells 
supports our biological function network (Figure 11). Significant upregulation of BTG2 
post-SV treatment (in a dose-dependent manner) confirms the role of this protein (Figure 
15). BTG2 downregulation has been reported as a p53 mutation gain of function since it 
results in unleashed Ras activation in immortalized primary human embryonic lung 
fibroblasts (WI-38 cells) (Solomon et al., 2012). 
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Figure 15. Relative expression of Res-related genes in mutant p53 MC10FAs. 
Validation of differentially expressed genes for p53R273H.MCF10A and p53G245S.MCF10A vs 
wtp53.MCF10A by RT-qPCR 
 
 Another pathway that is enriched after SV treatment in all the mutant and 
wtp53.MCF10As is FoxO signaling. Forkhead box O (FoxO) transcription factors have 
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important roles in stress resistance, metabolism, proliferation and apoptosis (Bergo et al., 
2004). FoxO proteins can get induced by activation of cell survival pathways PI3K/AKT 
and Ras/MAPK but also can be activated by stress-activated Jun N-terminal kinase (JNK) 
and the energy sensing AMP-activated protein kinase (AMPK) upon oxidative and nutrient 
stress.  Reverse-phase protein assay (RPPA) analysis on statin-treated and control breast 
cancer cells identified FoxO3a protein to be regulated by SV treatment (Wolfe et al., 2015). 
Consequently, FoxO signaling pathway is in part considered a key pro-apoptotic pathway 
in response to SV.   
 
In Figure 13 we observe very similar pattern of gene expression for mutant and 
wild-type p53. Most of these Ras family related genes expressed more after simvastatin 
treatment which can be explained by the same logic of increased HMGCR expression 
after inhibition. Surprisingly, dose dependent expression increase is not linear and that 
could mean at 20 µM cells are dying and gene expression level is not quite responsive to 
signaling inhibition anymore.    
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Figure 16. Relative gene expression post-statin in mutant and wild-type p53 cells. 
Validation of differentially expressed genes for p53R273H.MCF10A and p53G245S.MCF10A post SV- 
treated vs vehicle by RT-qPCR. Significantly altered genes are starred. Four stars are p<0.0005, 
Three stars are p<0.005, two stars are p<0.05. 
 
2.4.3. Prenylation inhibition blocks mp53-induced Ras and RhoA activation.  
To explore the mechanistic basis for the increased prenylation dependency in p53 
mutant cells, we evaluated the expression of Ras and RhoA because they require 
prenylation for signal transduction. We performed pull down experiments to probe for 
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RasGTP in mp53.MCF10A and wtp53.MCF10A cell lines. The Raf1-Ras binding domain 
was used for RasGTP immunoprecipitation, and the with Rhotekin-Rho binding protein 
was used for RhoA-GTP immunoprecipitation. Increased levels of RasGTP was observed 
in all mp53.MCF10A cell lines, while total Ras expression did not change (Figure 17). 
 
Figure 17. Ras and RhoA activation in mutant p53 MCF10As.  Immunoblot analysis of 
RasGTP, RhoAGTP, total Ras, and total RhoA expression in mp53 and wtp53.MCF10A before SV 
treatment and p53R248Q and p53Y234C after SV treatment at 10 µM. 
 
 This observation was consistent with the reported gain of function of mutant p53 
that elevates Ras activation through binding to BTG2 (Solomon et al., 2012).  Similarly, 
RhoA is synergistically activated by mp53 and active Ras. High expression of RhoA-GTP 
was observed, while total RhoA expression did not change with p53 mutation. To 
investigate the effect of SV treatment on the mp53-induced Ras-RhoA activation, we 
measured RasGTP, RhoAGTP, total Ras, and total RhoA expression after 5 µM 
simvastatin treatment for 48 hours. SV dramatically reduced both activated Ras and 
activated RhoA in mp53.MCF10A cells, disrupting the mp53/Ras/RhoA oncogenic 
collaboration. A schematic illustration of the cooperation of RasGTP and RhoGTP with 
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p53 mutation status is shown, with the sites of action of prenylation inhibitors noted 
(Figure 18).   
 
 
Figure 18. Schematic diagram of Ras activation. 
 
Based on this model, we predicted that mutations in p53 would increase Ras 
localization to the plasma membrane. Using confocal microscopy of wtp53 and 
mp53.MCF10A cell lines under serum starvation, the majority of Ras was localized to the 
plasma membrane. After SV treatment (5 µM for 48 hrs), a cytosolic expression pattern of 
Ras is observed, in particular in the mp53.MCF10A cell lines (Figure 19).  
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Figure 19. Ras translocation with SV treatment.  Immunofluorescence images of Ras 
in transduced MCF10A cells, before and after treatment with 5 µM SV treatment for 24 hrs. Grey: 
phase contrast, Blue: DAPI, Green: Ras. 
 
 
2.4.4. p53 mutation drives a Ras expression signature that correlates with 
simvastatin sensitivity 
 
Based on the evidence that p53 mutation promotes Ras activation and upregulates small 
GTPases, we sought to define a signature to identify cancers with these characteristics. 
We hypothesized that cancer cells harboring the signature would be more susceptible to 
prenylation inhibition. We used the RNA-Seq data of mp53 and wtp53.MCF10A before 
and after SV treatment to test our hypothesis. First, we grouped 17 breast cancer cell lines 
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into three groups based on TP53 status (wild-type; deletion, insertion, or nonsense 
mutation; and missense mutation). A box-plot of each group with the corresponding SV-
GI50 values derived from Broad Institute Cancer Cell line Encyclopedia (CCLE) is shown 
in Figure 20.  While overall p53 mutation increases SV sensitivity (p<0.05), missense 
mutation status alone was not predictive of SV response (WT vs FS: not significant; WT 
vs MIS: significant; FS vs MIS: not significant). Therefore, we derived a TP53-Ras 
regulated gene signature from 47 genes in the enriched Ras-related pathways of the two 
most sensitive cell lines (p53R273H and p53G245S.MCF10A). The baseline expression of 
these 47 genes are shown in a hierarchical clustered heatmap for mutant and 
wtp53.MCF10A cell lines (Figure 21-A). 18 genes (including ERBB2, SOS2 and MAPK3 
and the GTPase activator DLC1) positively correlate with SV sensitivity, and 29 genes 
(including E2F1 and ARHGDIB) negatively correlate with SV sensitivity. As explained in 
the method, we used a Random Forest to determine the 16 genes that were significantly 
associated with SV sensitivity (Figure 21-B). The final mP53-Ras (MPR) gene signature 
for SV response consists of RNA expression of 16 genes and mutation status of TP53.  
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Figure 20. p53 mutation is not a good predictor of GI50. Box-plot of 17 breast cancer 
cell lines based on TP53 genotype, wild-type (WT), FS (Deletion, insertion or nonsense), and 
missense (MIS). 
 
2.4.5. Prediction of Prenylation inhibition response in breast cancer cell lines 
We applied our Ras gene signature to the gene expression data of 17 breast cancer cell 
lines to test our SV prediction signature. Figure 22 demonstrates that 5 cell lines out of 6 
were correctly assigned ‘sensitive’ and 10 out of 11 were correctly assigned ‘resistant’ to 
SV. We next assessed whether PI sensitivity in our mp53.MCF10A cells correlates with 
the existing well-known breast cancer cell lines with the same p53 mutation. 
In Figure 23, our data confirms that there is a clear separation of killing curves 
between resistant cells (T47D, MCF7) and sensitive cells (MDA-MB-231, MBA-MB-468, 
SKBR3 and HCC70). We noticed that all the mutant p53 cell lines (except T47D) had high 
sensitivity to prenylation inhibition in comparison with MCF-7 which has wild-type p53. 
Similar to our observation with mp53.MCF10As, MDA-468 (R273H mutation) was 
strikingly sensitive to SV and HCC70 (R248Q mutation) was less sensitive. 
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     A                                                                    B 
 
 
Figure 21. Ras-related gene signature of SV sensitivity. A) Supervised hierarchical 
clustering Log2 expression of 47 Ras-related genes for mp53.MCF10As and wtp53.MCF10A. B) 
Pearson correlation coefficient-based heatmap representation of genes with significant correlation 
with SV sensitivity. SV: simvastatin. 
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Figure 22. Prediction of simvastatin response in breast cancer cell lines. 
Classification of 17 breast cancer cell lines using the MPR gene signature. NCI-60 GI50 value 
used to classify. GI50 of 20 µM is considered to be the cut off. GI50≤20 µM =sensitive. GI50>20 
µM=Resistant. Prediction accuracy is 89%. 
 
It is important to consider other characteristics of these breast cancer cell lines 
(summarized in Fig.5C) to realize why T47D as a mutant p53 cell line is not very 
dependent on prenylation. As it is reported by Eckert.et al, RasGTP expression of T47D 
is as low as a wild-type p53 cell line such as MCF-7 (Eckert et al., 2004). 
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Figure 23. Breast cancer cell line sensitivity to simvastatin. Sensitivity of MDA-MB-
231, MDA-MB-468, MCF-7, HCC70, SKBR3 and T47D to SV is confirmed by proliferation 
inhibition assay. Proliferation is reported as alive treated cells percentage of total alive vehicle 
treated cells at 0, 2.5, 5, 10, 15, 20 and 30 µM concentration after 48 hrs. 
 
Next, we decided to apply our signature to predict response to all the prenylation 
inhibitors from the NCI-60 drug screening database. NCI-60 has GI50 values for 
simvastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, atorvastatin, and zoledronate 
for five breast cancer cell lines (MDA-MB-231, HS578T, BT549, T47D, MCF-7). Our 
signature successfully predicts the response to prenylation inhibition for all the five cell 
lines (Figure 24).  
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Figure 24. Prediction of prenylation inhibitors to breast cancer cell lines. MPR 
signature is applied to predict drug response to different prenylation inhibitors (PIs) in the 
mentioned breast cancer cell lines from NCI-60 database. 
 
2.4.6. Ras signature is used to predict simvastatin response in breast cancer 
patients 
 
Having identified a mp53-Ras regulated (MPR) gene signature to predict PI’s 
anticancer response in breast cancer cell lines, we next examined this signature using a 
dataset from a pre-operative statin trial of breast cancer (Bjarnadottir et al., 2013). Gene 
expression from 25 paired pre- and post-atorvastatin tumor samples is used for classifying 
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into two groups of potential responders and non-responders by our MPR signature. 
Response to statin is assessed by the gene expression of proliferation marker Ki67 post- 
vs pre-statin, noted as the defined end point in this trial (Bjarnadottir et al., 2013). In our 
model, statin users were predicted to be 9 responders and 16 non-responders with no 
significant differences in expression of MKI67 (gene coding Ki67). Statin treatment 
significantly altered 1412 genes in responder group and 2670 genes in non-responders 
with 660 genes common in two groups (Fig.6A).  
 
 
 
Figure 2-25. Differentially expressed genes post statin in two group pf MPR+ and 
MPR- patients. A) Classification of 25 newly diagnosed breast cancer patients into 9 responders 
and 16 non-responders using our prediction signature. TP53 status is not known and excluded 
from the signature. Paired pre-post treated differential gene expression analysis shows 1412 
genes in responders and 2670 genes in non-responders are significantly altered and 660 genes 
are common between the two groups (P<0.05). 
 
 
Gene ontology analysis of differential gene expression analysis of two groups 
present different patterns of gene enrichment between responders and non-responders 
(Figure 2-25). Expectedly, common enriched pathways between responders and non-
responders are related to lipid lowering effect of statin; SREBP and other cholesterol 
biosynthesis transcription factors gene expression, cytokines and other immune 
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regulatory modulations, integrin interactions and NF-kappa B transcription pathway 
Figure 26. 24 and 27-hydroxycholesterol bile acid synthesis are also among the common 
pathways that are changed post-statin in both groups. 
 
 
 
Figure 26. MPR signature is applied to predict response in patients treated with 
atorvastatin presurgically. Gene ontology analysis shows different pattern of enriched 
pathways among predicted to be responders and non-responders. 
 
The major difference between the two groups is the highly enriched cell arrest and stress-
induced pathways in responders that dominates all other cell events. On the other side, 
we observe regular growth and energy metabolism -related signaling events that are 
52 
targeted by statin, hence FoxO signaling is showing up as we have encountered it for our 
cell lines’ post-statin pathway analysis Figure 26. 
 
2.5. DISCUSSION 
 
Current lack of biomarker studies of the anticancer efficacy of any of the PIs raised the 
challenge of selecting patients prospectively for clinical trials. Most cancer biomarkers are 
selected based on the statistically significant differences in an unselected population 
without adequate link to the molecular basis and tumor type. Here, we used pre-clinical 
studies to select our marker candidates for statin response. We used the Ras/Rho 
signaling associated genes whose expression was highly correlated with SV response in 
mp53.MCF10A cells to define a mp53-Ras regulated (MPR) gene signature. This 
signature was validated in breast cancer cell lines, both in response to statins and 
zoledronate. Using expression data from a breast cancer neoadjuvant trial of atorvastatin 
(n=25), we predicted 9 MPR+ patient. After two weeks of statin treatment, gene expression 
of these two groups represented major differences in drug response using gene ontology 
analysis. Tumors from patients predicted to be statin responders showed increased 
oxidative stress and DNA damage. Our Ras gene signature includes 16 genes and TP53 
mutation status as wild type, missense, and other mutations.  
Recent findings on the sensitivity of mp53 cells to the mevalonate pathway 
inhibition provides a unique opportunity to tackle over 40 percent of tumors in breast 
cancer. Although p53 sensitivity to statin has been explained by upregulation of sterol 
biosynthesis genes, the addback of cholesterol is not sufficient to rescue the effect. Our 
data is consistent with a large body of pre-clinical studies on statins but in the context of 
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p53 mutation gain of function. Based on the gene ontology results (Appendix A), SV 
treatment upregulates genes in sterol biosynthesis and fatty acid synthesis; alters 
membrane composition by changing lipid saturation; and deregulates interactions 
between integrins, epidermal growth factor and cytokine receptors. Hippo signaling, 
adhesion and migration signaling pathways are highly impaired presumably due to direct 
dependence on GTPases. SV induces mTOR and AMP-activating protein (AMPK), a 
central sensor of cellular energy metabolism. In addition to oxidative stress, impaired 
MAPK and PI3K signaling, and importantly inhibition of histone deacetylase activity results 
in FoxO3a-dependent apoptotic pathway signaling. Our biochemical data confirms that 
mutant p53 cancer cells are more dependent on Ras and RhoA for their transforming 
activity and survival. Add-back experiments demonstrates that either 
farnesylpyrophosphate or geranylgeranylpyrophosphate was enough to reverse the statin 
proliferation inhibition effect. This clarifies that prenylation deprivation is the main reason 
for successful inhibition of mp53-tumor growth by SV.  
Dominant-negative effect of mp53 over wild-type p53 is complex and depends on 
the context off interaction with transcription factors and other proteins directly.  We used 
MCF10A cells to minimize the effect of existing oncogenic collaborators to be able to 
understand the strategy of mutant p53 cells to thrive and transform. It is important to 
recognize that tumor heterogeneity is a huge barrier for the clinical implication of a target 
study, and we generated a mp53-regulated Ras signature to overcome this. Our data 
suggests that the mevalonate pathway blockade can be even more effective in cancers 
with oncogenic GTPase signaling such as prostate cancer. Although Ras mutation is 
infrequent in breast cancer, there is over 90% mutation frequency for some other cancer 
types (e.g., pancreatic, colon). There is an urgent need to characterize all the proteins that 
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require prenylation for their normal function and their role in cancer. FTIs and GTIs can be 
more potent if prenylation requirement of the tumor target is recognized and applied in 
clinical trial design. No doubt, our predictive gene signature could improve using large 
clinical datasets with genome, transcriptome, and clinical information which does not exist 
yet. 
Over two decades of efforts in developing PIs specially FTIs to target the Ras 
genes, the most common oncogenic activating mutations, did not provide any survival 
benefit for the patients. Nonetheless, the biological role of prenylation is gaining more 
attention due to its crucial contribution in RasGTPase and RhoGTPase malignant 
transforming activities. Today, we have a better understanding that KRAS and HRAS can 
use either farnesylation or geranylgeranylation as their lipid modification and this can be 
the reason for KRAS tumor resistance to FTIs (M. Wang & Casey, 2016). Identification of 
proteins critical for a certain tumor that are exclusively either farnesylated or geranylated 
can give PIs a clinically meaningful improvement. For instance, the FTI antitumor effect 
does not rely on Ras activation status in prostate cancer cells and other downstream 
prenylated proteins such as RALA and RALB could be of importance (Lim et al., 2005) . 
However, targeting HMG-CoA reductase, upstream of prenylation, can limit both 
farnesylation and geranylgeranylation with the added benefit of inhibiting mevalonate 
kinase. Mevalonate kinase is reported to be associated with mp53 misfolding (W. Freed-
Pastor & Prives, 2016; Parrales et al., 2016). We conclude that Inhibiting the mevalonate 
pathway will target mp53- Ras induced -RhoA axis effectively by mp53 degradation, 
changing the cellular Ras distribution and inhibiting Rho signaling. 
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CHAPTER 3 
 GENE THERAPY USING CRISPR-CAS9 SYSTEM 
 
3.1. INTRODUCTION AND BACKGROUND 
 
The CRISPR/Cas9 gene-editing tool has raised hopes for developing personalized 
treatments for complex diseases such as genetic disorders and cancer, which are 
currently in clinical trials (Cyranoski, 2016; Reardon, 2016).  This excitement comes after 
a history of optimism and disappointment about the potential of gene therapy engendered 
by impressive success stories and serious adverse events (Cavazzana-Calvo et al., 2000; 
Cyranoski, 2016; Gaspar et al., 2004; Hacein-Bey-Abina et al., 2002; Howe et al., 2008; 
Manno et al., 2006; Marshall, 1999; Reardon, 2016).  The expression of Cas9 in mice has 
been recently shown to evoke both cellular and humoral immune responses (Chew et al., 
2016; J. Wang et al., 2013), which raises concerns regarding its safety and efficacy as a 
gene therapeutic.  Lessons learned from the host immune reactions to the numerous 
exogenous gene delivery systems under investigation (Mays & Wilson, 2011; Mingozzi et 
al., 2013; Yin et al., 2014) suggest that this immunogenicity is potentially disruptive.  
Both B-cell and T-cell host responses specific to either the transgene or the viral 
components of the adenoviral (Ahi, Bangari, & Mittal, 2011; Aldhamen & Amalfitano, 2016) 
and adeno-associated viral (AAV) (Ahi et al., 2011; Aldhamen & Amalfitano, 2016; Mays 
& Wilson, 2011; Mingozzi et al., 2013) vectors have been detected, despite known low 
immunogenicity of AAV.  The potential consequences of this immune response include 
neutralization of the gene product; destruction of the cells expressing it leading to loss of 
therapeutic activity or tissue destruction; memory effect that prevents re-administration; 
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and violent innate inflammatory response (Brunetti-Pierri & Ng, 2009; Halbert, Standaert, 
Wilson, & Miller, 1998; H. Jiang et al., 2006; Kay, 2011; Nathwani et al., 2011).  Another 
crucial concern facing the translation of gene manipulation techniques to humans is the 
more drastic immune response observed in humans and large-animal models compared 
with mice (Gao et al., 2009; Manno et al., 2006).  The transgene expression, although 
sustained in animal models, is short-lived in humans (Manno et al., 2006), likely as a 
consequence of the immune response (Mingozzi et al., 2007).   
Due to natural exposure, pre-existing immunity directed against the vector and less 
commonly the transgene is a common challenge in gene therapy.  In the case of AAV, 
specific neutralizing antibodies and T cells are frequently detected in healthy donors 
(Boutin et al., 2010; Mingozzi et al., 2007; Thwaite, Pages, Chillon, & Bosch, 2015) and in 
contrast to mice, specific CD8+ T cells were shown to expand following gene delivery 
(Mingozzi et al., 2007).  There has been recent progress in developing strategies to 
overcome this problem (Bartel, Schaffer, & Buning, 2011; Martino et al., 2013; Mingozzi 
et al., 2013).  Of the various Cas9 orthologs from different bacterial species studied (Esvelt 
et al., 2013; Hirano et al., 2016; Ran et al., 2015; Zetsche et al., 2015), the Streptococcus 
pyogenes Cas9 (SpCas9) is the best characterized.  Being a bacterial protein, SpCas9 is 
likely to trigger cellular and humoral immune reaction in humans, as was demonstrated in 
naïve mice (Chew et al., 2016; J. Wang et al., 2013).  More alarmingly, the ubiquity of S. 
pyogenes with 700 million infections annually (Carapetis, Steer, Mulholland, & Weber, 
2005), suggests that pre-existing immunity to SpCas9 in healthy individuals is a 
reasonable concern.   
Cas9-specific T-cell activation and proliferation were confirmed in an expanded 
CD45+ cell population following in vivo expression of Cas9 delivered by an AAV vector or 
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DNA electroporation in mice (Chew et al., 2016).  This highlights the need to characterize 
the immunogenicity of Cas9 in humans as this gene-editing technology is moving to the 
clinic.  Here, we sought to characterize the pre-existing immune response to SpCas9 in 
healthy individuals and to identify the immunodominant T-cell epitopes with the aim of 
modulating Cas9 immunogenicity.  
 
3.2. MATERIALS AND METHODS 
 
3.2.1. Detection of Cas9-Specific Serum Antibodies in Healthy Controls 
 
Healthy control sera (n = 183) used in this study, previously described (Anderson 
et al., 2015) [38], are a subset of a molecular epidemiology study of head and neck cancer 
at the MD Anderson Cancer Center, collected between January 2006 and September 
2008. S. pyogenes lysate was prepared by sonication of bacterial pellets from overnight 
cultures of S. pyogenes ATCC 19615 in the presence of 1 pill of cOmplete Protease 
Inhibitor (Sigma-Aldrich) after 3 cycles of freezing and thawing.  Serum antibody detection 
was performed using ELISA.  96-well plates were coated with of 20 μg/mL recombinant 
S. pyogenes Cas9 nuclease (New England Biolabs, Ipswich, MA) or S. pyogenes lysate.  
Sera were diluted 1:50 in 10% E. coli lysate prepared in 5% milk-PBST (0.2% tween) (D. 
Wang et al., 2015), incubated with shaking for 2 h at room temperature, and added to the 
specified wells in duplicate.  Horseradish peroxidase (HRP) anti-human IgG Abs (Jackson 
ImmunoResearch Laboratories, West Grove, PA) were added at 1:10,000, and detected 
using Supersignal ELISA Femto Chemiluminescent substrate (Thermo Fisher Scientific, 
Waltham, MA).  Luminescence was detected as relative light units (RLU) on a Glomax 96 
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Microplate Luminometer (Promega, Madison, WI) at 425 nm.  To establish cut-off values, 
an RLU ratio > (the mean +3 standard deviations) of 125 randomly chosen control samples 
was designated positive.  
 
3.2.2. Cas9 candidate T cell epitope prediction 
 
We used our previously described prediction strategies (Chowell et al., 2015; 
Krishna & Anderson, 2016) to predict candidate Cas9 T cell epitopes.  Briefly, we predicted 
HLA-class I restricted 9-mer and 10-mer candidate epitopes derived from the Cas9 protein 
(Uniprot - Q99ZW2) for HLA A*02:01.  The protein reference sequence was entered into 
5 different prediction algorithms; 3 MHC-binding : IEDB-consensus binding (Moutaftsi et 
al., 2006) [41], NetMHCpan binding (Hoof et al., 2009), Syfpeithi (Rammensee, 
Bachmann, Emmerich, Bachor, & Stevanović, 1999) and 2 antigen-processing algorithms: 
IEDB-consensus processing, ANN processing (Tenzer et al., 2005) [44]. The individual 
scores from each of the prediction algorithms were then normalized within the pool of 
predicted peptides after exclusion of poor binders as previously detailed (Chowell et al., 
2015; Krishna & Anderson, 2016), and the average normalized binding scores were used 
to re-rank the candidate peptides. The top 38 candidate peptides (Table 1) were selected 
for experimental testing. 
 
3.2.3. Ex vivo stimulation and epitope mapping of Cas9 by ELISpot 
 
All peripheral blood mononuclear cells (PBMCs) were obtained from healthy 
donors using informed consent under IRB# MOD00006783. PBMCs were isolated from 
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fresh heparinized blood by Ficoll–Hypaque (GE Healthcare, UK) density gradient 
centrifugation and stimulated as previously described [40].  Briefly, predicted Cas9 
peptides (> 80% purity) were synthesized by Proimmune, UK.  Each peptide was 
reconstituted at 1mg/mL in sterile PBS and pools were created by mixing 3-4 candidate 
peptides.  Sterile multiscreen ELISpot plates, (Merck Millipore, Billerica, MA, USA) were 
coated overnight with 5μg/well of anti-IFNγ capture antibody (clone D1K, Mabtech, USA) 
diluted in sterile PBS.  Frozen PBMCs were thawed rapidly and recombinant human IL-2 
(20U/mL) was added.  They were then stimulated in triplicates with 10μg/mL Cas9 peptide 
pools (or individual peptides for deconvolution), pre-mixed CEF pool as a positive control 
(ProImmune, UK), or DMSO as a negative control in the anti-IFNγ-coated ELISpot plates, 
(Merck Millipore, Billerica, MA, USA) and incubated in a 37°C, 5% CO2 incubator for 48 
hours.  Plates were washed three times for 5 min each with ELISpot buffer (PBS + 0.5% 
FBS) and incubated with 1μg/mL anti-IFNγ secondary detection antibody (clone 7-B6-1, 
Mabtech, USA) for 2 hours at room temperature, washed and incubated with 1μg/mL 
Streptavidin ALP conjugate for 1 hour at room temperature.  The wells were washed again 
with ELISpot buffer and spots were developed by incubating for 8-10 min with detection 
buffer (33μL NBT, 16.5μL BCIP, in 100mM Tris-HCl pH 9, 1mM MgCl2, 150mM NaCl).  
Plates were left to dry for 2 days and spots were read using the AID ELISpot reader 
(Autoimmun Diagnostika GmbH, Germany).  The average number of spot forming units 
for each triplicate was calculated for each test peptide or peptide pool and subtracted from 
the background signal.  
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3.2.4. Autologous APC generation from healthy donor PBMCs 
 
Autologous CD40L-activated B-cell APCs were generated from healthy donors by 
incubating whole PBMCs with irradiated (32 Gy) K562-cell line expressing human CD40L 
(KCD40L) at a ratio of 4:1 (800,000 PBMCs to 200,000 irradiated KCD40Ls) in each well.  
The cells were maintained in B-cell media (BCM) consisting of IMDM (Gibco, USA), 10% 
heat-inactivated human serum (Gemini Bio Products, CA, USA), and Antibiotic-
Antimycotic (Anti-Anti, Gibco, USA).  BCM was supplemented with 10 ng/mL recombinant 
human IL-4 (R&D Systems, MN, USA), 2μg/mL Cyclosporin A (Sigma-Aldrich, CA, USA), 
and insulin transferrin supplement (ITES, Lonza, MD, USA).  APCs were re-stimulated 
with fresh irradiated KCD40Ls on days 5 and 10, after washing with PBS and expanding 
into a whole 24-well plate.  After two weeks, APC purity was assessed by CD19+ CD86+ 
expressing cells using flow cytometry, and were used for T-cell stimulation after >90% 
purity.  APCs were either restimulated up to 4 weeks or cryopreserved for re-expansion 
as necessary.  
 
3.2.5. T-cell stimulation by autologous APCs 
 
Antigen-specific T-cells were generated by stimulating healthy donor B-cell APCs 
by either peptide pulsing of specific Cas9 epitopes, or by transfecting with the mammalian 
expression plasmid pCDNA3.2 (Invitrogen, CA, USA) encoding the whole Cas9 protein.  
Peptide pulsing of APCs was done under BCM 5% human serum, with recombinant IL-4.  
Transfection of APCs was done with primary P3 buffer in a Lonza 4D Nucleofector and 
program EO117 (Lonza, MD, USA) and incubated in BCM-10% human serum and IL-4.  
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Twenty-four hours later, on day 1, APCs were washed and incubated with thawed whole 
PBMCs at a ratio of 1:2 (200,000 APCs : 400,000 PBMCs) in a 24-well plate in BCM 
supplemented with 20U/mL recombinant human IL-2 (R&D Systems, MN, USA) and 
5ng/mL IL-7 (R&D Systems, MN, USA).  On day 5, partial media exchange was performed 
by replacing half the well with fresh B-cell media and IL-2.  On day 10, fresh APCs were 
either peptide pulsed or transfected as described above in a new 24-well plate.   On day 
11, expanded T-cells were restimulated with peptide-pulsed, transfected APCs similar to 
day 1.  T-cells were used for cytolytic assays or immunophenotyped after day 20.  
 
3.2.6. Flow cytometry staining for T-cell 
Cells were washed once in MACs buffer (containing PBS, 1% BSA, 0.5mM EDTA), 
centrifuged at 550g for 5 min and re-suspended in 200μL MACS buffer.  Cells were stained 
in 100μL of staining buffer containing anti-CD137, conjugated with phycoerythrin (PE, 
clone 4B4-1; BD Biosciences, USA), anti-CD8-PC5 (clone B9.11; Beckman Coulter 
1:100), anti-CD4 (clone SK3; BioLegend, 1:200), anti-CD14 (clone 63D3; BioLegend, 
1:200), and anti-CD19 (clone HIB19; BioLegend,1:200), all conjugated to Fluorescein 
isothiocyanate (FITC) for exclusion gates, for 30 min on ice.  Samples were covered and 
incubated for 30 min on ice, washed twice in PBS, and resuspended in 1mL PBS prior to 
analysis.  
 
3.2.7. Pentamer staining for T-cell immunophenotyping  
 
The following HLA-A*02:01 PE-conjugated Cas9 pentamers were obtained from 
ProImmune.  T-cells were washed twice in MACS buffer with 5% human serum and 
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centrifuged at 550g for 5 min each time.  They were then re-suspended in 100μL staining 
buffer (MACS buffer, with 5% human serum and 1mM Dasatanib (ThermoFisher Scientific, 
MA, USA).  Each of the pentamers was added to resuspended T-cells stimulated with the 
respective peptide or APCs at a concentration of 1:100.  Samples were incubated at room 
temperature for 30 min in the dark, then washed twice in MACS buffer.  Cells were stained 
in 100μL MACS buffer with anti-CD8-PC5, anti-CD4-FITC, anti-CD14-FITC, and anti-
CD19-FITC for exclusion gates, for 30 min on ice.  Samples were then washed twice with 
PBS and analyzed by flow cytometry.  For flow cytometric analysis, all samples were 
acquired with Attune flow cytometer (ThermoFisher Scientific, MA, USA) and analyzed 
using the Attune software. Gates for expression of different markers and pentamers were 
determined based on flow minus one (FMO) samples for each color after doublet 
discrimination.  Percentages from each of the gated population were used for the analysis. 
 
 
3.3. RESULTS 
3.3.1. Detection of Cas9-Specific Serum Antibodies in Healthy Controls 
 
We first investigated whether healthy donors, in particular those with previous exposure 
to Streptococcus pyogenes, have detectable IgG Abs to Streptococcus pyogenes Cas9 
(SpCas9).  Of 143 healthy control sera screened, 49.0% had detectable Abs against S. 
pyogenes lysate using ELISA. This positive subset along with 12 of the sera negative for 
S. pyogenes lysate that had the highest RLU value were screened for Abs against 
recombinant Cas9. We detected Cas9-specific Abs in at least 21.0% (n=30) of all sera 
screened (Figure 27).  
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Figure 27. Serum antibody detection against S. pyogenes and Cas9. Specific serum 
Abs were detected against S. pyogenes lysate in 49.0% (above the dotted line) of 143 healthy 
controls (left).  The subset shown in black circles was screened for Abs against recombinant 
Cas9 protein (right), of which 36.6% (21.0% of total samples screened) were positive.   
 
 
3.3.2. In silico prediction of Cas9 immunogenic T cell epitopes 
 
Probability and a peptide immunogenicity probability, we prioritized Cas9 peptides with 
predicted high binding and high immunogenicity (Chowell et al., 2015) ( 
Table 3).   
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In brief, IEDB consensus MHC-binding prediction algorithm (http://www.iedb.org/) was 
applied to obtain a list of high binding Cas9 peptides for HLA-A*02:01, each of which was 
assigned a normalized binding score (Sb).  Next, an immunogenicity score (Si) was 
calculated for each peptide based on its amino acid hydrophobicity.  According to this 
prediction model,  
 
Table 3. Binding and processing scores for Cas9 epitopes. the Cas9 HLA-A*02:01 
epitopes predicted using IEDB and Syfpathi prediction software. The immunodominant epitopes 
are highlighted in dark gray.  Other predicted immunogenic peptides confirmed via ELISpot assay 
are highlighted in light gray. 
 
Aminoacid 
Position 
Epitope 
Sequence 
Code IEDB 
bind 
NetMHC 
bind 
Syfpeithi 
bind 
IEDB 
prot 
ANN 
prot 
1041-1050 YLNAVVGTAL 98 1.25 21.5 24 0.27 0.02 
1334-1343 ILADANLDKV 81 1.25 11.37 31 -0.06 -0.49 
289-297 GLFGNLIAL 84 0.6 10.12 29 1.15 1.04 
293-301 NLIALSLGL 94 1.7 61.18 25 0.15 0.22 
668-676 ILEDIVLTL 85 1.5 53.29 29 0.28 0.56 
667-676 DILEDIVLTL 96 4.6 3105.79 28 -1.53 -1.02 
468-476 HLGELHAIL 99 4.4 276.73 25 -0.75 -0.81 
353-361 ILLSDILRV 83 0.3 6.51 29 0.67 0.7 
1139-1148 VLSMPQVNIV 93 3.65 178.87 26 -1.05 -1.43 
1399-1408 TLIHQSITGL 88 1.95 57.8 27 0.12 -0.06 
1250-1259 KLPKYSLFEL 87 1.2 10.93 27 0.9 0.5 
565-573 SLLYEYFTV 92 0.4 4.56 25 0.67 0.55 
1280-1289 ALPSKYVNFL 91 4.3 111.14 27 0.05 -0.26 
1049-1057 ALIKKYPKL 86 2.6 154.09 28 -0.27 0 
274-282 RLENLIAQL 95 4.2 242.87 26 -0.46 -0.46 
1290-1298 YLASHYEKL 90 1.2 10.3 26 0.9 0.84 
795-803 KVVDELVKV 40 2.8 44.75 24 -0.06 -0.26 
772-780 SLHEHIANL 82 1.4 9.14 30 0.93 0.82 
1318-1326 YLDEIIEQI 89 0.3 4.8 26 0.62 0.6 
604-613 LLFKTNRKV 97 3 381.3 25 -1.52 -1.25 
772-781 SLHEHIANLA 13 4.7 60.17 19 -0.98 -1.74 
1247-1256 LIIKLPKYSL 3 8.5 966.31 25 -0.97 -1.04 
1094-1103 NIMNFFKTEI 12 2.65 314.8 19 -1.03 -0.9 
1362-1371 IIHLFTLTNL 2 4.25 1083.6 24 -1.04 -0.78 
714-723 RLSRKLINGI 17 3.5 278.03 24 -0.82 -1.05 
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1095-1103 IMNFFKTEI 7 3.2 131.4 21 -0.69 -0.87 
868-877 YLQNGRDMYV 1 0.25 13.01 22 -0.18 -0.07 
1265-1273 RMLASAGEL 4 3.2 333.2 22 -0.64 -0.51 
1073-1082 KMIAKSEQEI 5 3.1 64.01 21 -0.36 -0.9 
846-854 SQILKEHPV 19 2.8 191.23 16 -1.4 -1.36 
1234-1243 FLEAKGYKEV 6 3.25 105.27 21 -1.08 -1.42 
213-222 HMIKFRGHFL 9 4.75 324.13 21 -0.59 -0.73 
194-203 KLVDSTDKA 11 3.4 274.05 20 -1.48 -1.17 
525-534 TITPWNFEEV 8 4.45 124.55 21 -0.84 -1.21 
247-256 QLFEENPINA 15 1.65 67.94 17 -0.71 -0.79 
571-580 FTVYNELTKV 10 2.55 169.93 20 -1.12 -1.15 
526-534 ITPWNFEEV 14 6.4 351.14 18 -1.25 -1.65 
1023-1031 FQFYKVREI 18 2.7 135.61 16 -0.66 -0.39 
 
 
 
Table 4. Predicted Cas9 immunogenic T cell epitopes. the Cas9 HLA-A*02:01 
epitopes predicted using our prediction model and ranked according to their Si.Sb score.  The 
immunodominant epitopes are highlighted in dark gray.  Other predicted immunogenic peptides 
confirmed via ELISpot assay are highlighted in light gray. 
 
Aminoacid 
Position 
Epitope 
Sequence 
Binding 
score 
Sum 
proc 
ANN Hydro Sb.Si Rank 
1041-1050 YLNAVVGTAL 0.068 0.027 0.975 0.002 1 
1334-1343 ILADANLDKV 0.003 0.054 0.447 0.002 2 
289-297 GLFGNLIAL 0.02 0.214 0.9 0.002 3 
293-301 NLIALSLGL 0.061 0.036 0.903 0.006 4 
668-676 ILEDIVLTL 0.023 0.082 0.71 0.007 5 
667-676 DILEDIVLTL 0.063 0.248 0.888 0.007 6 
468-476 HLGELHAIL 0.071 0.152 0.876 0.009 7 
353-361 ILLSDILRV 0.019 0.134 0.404 0.011 8 
1139-1148 VLSMPQVNIV 0.059 0.243 0.758 0.014 9 
1399-1408 TLIHQSITGL 0.043 0.017 0.632 0.016 10 
1250-1259 KLPKYSLFEL 0.04 0.136 0.579 0.017 11 
565-573 SLLYEYFTV 0.056 0.119 0.678 0.018 12 
1280-1289 ALPSKYVNFL 0.051 0.03 0.594 0.021 13 
1049-1057 ALIKKYPKL 0.037 0.025 0.407 0.022 14 
274-282 RLENLIAQL 0.061 0.089 0.581 0.026 15 
1290-1298 YLASHYEKL 0.05 0.17 0.446 0.027 16 
795-803 KVVDELVKV 0.074 0.031 0.505 0.036 17 
772-780 SLHEHIANL 0.013 0.171 0.38 0.008 18 
1318-1326 YLDEIIEQI 0.046 0.119 0.399 0.028 19 
604-613 LLFKTNRKV 0.067 0.27 0.368 0.043 20 
772-781 SLHEHIANLA 0.126 0.268 0.89 0.014 21 
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1247-1256 LIIKLPKYSL 0.09 0.197 0.841 0.014 22 
1094-1103 NIMNFFKTEI 0.121 0.188 0.857 0.017 23 
1362-1371 IIHLFTLTNL 0.085 0.177 0.787 0.018 24 
714-723 RLSRKLINGI 0.078 0.183 0.746 0.02 25 
1095-1103 IMNFFKTEI 0.103 0.153 0.724 0.028 26 
868-877 YLQNGRDMYV 0.083 0.023 0.627 0.031 27 
1265-1273 RMLASAGEL 0.095 0.112 0.65 0.033 28 
1073-1082 KMIAKSEQEI 0.103 0.124 0.671 0.034 29 
846-854 SQILKEHPV 0.149 0.27 0.766 0.035 30 
1234-1243 FLEAKGYKEV 0.103 0.245 0.651 0.036 31 
213-222 HMIKFRGHFL 0.11 0.129 0.628 0.041 32 
194-203 KLVDSTDKA 0.114 0.259 0.52 0.055 33 
525-534 TITPWNFEEV 0.107 0.201 0.429 0.061 34 
247-256 QLFEENPINA 0.135 0.146 0.469 0.072 35 
571-580 FTVYNELTKV 0.111 0.222 0.216 0.087 36 
526-534 ITPWNFEEV 0.143 0.285 0.229 0.11 37 
1023-1031 FQFYKVREI 0.148 0.102 0.229 0.114 38 
 
peptides with low Sb (high binders) and high Si (more hydrophobic) are expected to be 
more immunogenic ( 
 
Table 4, Figure 28).    
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Figure 28. Improved epitope prediction model with applying immunogenicity score. 
Red dots represent epitopes that were shown immunogenic by ELISpot. Sb is normalized binding 
score, Si is immunogenicity score. 
 
3.3.3. Identification of two Cas9 immunodominant T cell epitopes  
 
We sought to determine whether healthy donor peripheral blood mononuclear cells 
(PBMCs) displayed T cell reactivity against predicted Cas9 MHC class I epitopes.  
We synthesized the top 38 peptides and grouped them into 10 pools (each 
containing 3 or 4 peptides) for screening memory T cell response in healthy 
individuals using ELISpot.  We tested the reactivity of 12 healthy donor peripheral 
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blood T cells to each peptide pool and found consistently high reactivity to pools 3 
and/or 5 in 83% of the donors tested (Figure 29).   
 
 
Figure 29. IFNγ ELISpot assay acreening for T cell reactivity. Twelve healthy 
idividuals were tested for 38 predicted epitopes grouped in 10 pools, CEF (positive control), and 
DMSO (negative control). 
 
These 38 predicted epitopes cover about 30% of the Cas9 protein and their 
reactivity and position within the protein are shown in Figure 30.  Upon deconvolution of 
pools 3 and 5 (7 peptides in total), the dominant immunogenic peptides were found to be 
85 and 94, although reactivity to other peptides was also occasionally detected in some 
of the donors.  The identified immunogenic epitopes are shown as red dots on the epitope 
prediction plot and the immunodominant epitopes (94 and 85) are labeled (Figure 37).  As 
predicted, these peptides are more immunogenic as shown by their low Sb and high Si 
scores.   
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Figure 30. Reactivity of healthy donor T cells with the HLA types shown to epitopes 
across the different domains of the Cas9 protein. 
 
 
3.3.4. Modified Cas9 with mutated epitope(s) is less immunogenic while retaining 
its function 
 
We hypothesized that mutation of the anchor residues of the identified 
immunogenic epitopes (94 and 85, Figure 30) will abolish the specific T cell immune 
response detected in positive donors.  We created 3 modified cas9 constructs by mutating 
the second residue of peptide 94 (L294G; cas9-10), peptide 85 (L669G; cas9-01), or both 
(cas9-11) and tested their immunogenicity and function in comparison with wild-type cas9 
(cas9-00).  We also tested the reactivity of healthy donor PB T cells to modified peptides 
94 and 85 with mutations in residues 2, 9, or both (Figure 31) using ELISpot. 
We also tested the reactivity of healthy donor peripheral blood T cells to WT 
epitopes 94 and 85 or their modified versions with mutations in residues 2, 9, or both 
70 
(Figure 32) by using an IFN-γ ELISpot assay. We detected high epitope-specific T cell 
reactivity that was abolished or reduced with the mutant peptides 94 (Figure 32A) and 85 
(Figure 32B).  
Figure 31 shows the triplicate ELISpot wells for each peptide, the positive control 
(CEF), and the negative control (DMSO). 
 
 
 
 
Figure 31. ELISpot assay for screening healthy donors’ PBMCs to Cas9 epitopes. 
ELlSpot assay comparing the T cell response to epitope 85 and 94 to their mutated peptides. 
Mutation to glycine has been introduced to amino acid position second or nine or both in peptide 
85 and 94. CEF is used as a positive control. DMSO is used as the negative control. 
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Figure 32. Decreasing T cell response to epitope 85 and 94 by mutating the 
epitope. Twelve health donors were tested for T cell response reduction upon mutation at te 
second or nine residue or both. Donor’s HLA type is specified for the ones that are HLA-typed.  
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Mutated Cas9 proteins successfully recognized and bound their target DNA 
leading to enhanced target gene expression (Figure 33A).  HEK293 cells were transfected 
with a plasmid encoding Infrared Fluorescent Protein (IRFP; an exogenous gene driven 
by a synthetic CRIPSR-activated promoter), with or without plasmids encoding MS2-P65-
HSF1 (an activation mediator that activates the transcription of the target gene), WT (cas9-
00) or mutated cas9 gene (cas9-01, -10, or -11), and 14nt gRNA targeting IRFP.  Mutated 
Cas9 proteins also successfully recognized and bound to their target DNA leading to 
enhanced endogenous (chromosomal) target gene expression. HEK293 cells were 
transfected with plasmids encoding MS2‐P65‐HSF1 (an activation mediator that activates 
the transcription of the target gene) and 14-nt gRNA targeting the promoter regions of a 
gene encoding structural protein (TTN, Figure 33A), or a long noncoding RNA (MIAT, 
Figure 33B) with or without a plasmid encoding WT (cas9-00) or mutated cas9 gene (cas9-
01, -10, or -11). 
Mutated Cas9 proteins also successfully recognized and bound their target DNA 
leading to repression of target gene expression (Figure 33B).  HEK293 cells were 
transfected with a plasmid encoding Yellow Fluorescent Protein (YFP; an exogenous gene 
driven by a synthetic constitutive promoter comprised of two mini CMVs and two CRISPR 
biding sites), with or without plasmids encoding WT (cas9-00) or mutated cas9 gene 
(cas9-01, -10, or -11), and 20nt gRNA targeting YFP.  The expression of IRFP and YFP 
was measured by flow cytometry. Mutated Cas9 protein (Cas9-11) successfully 
recognized and bound its target DNA leading to the introduction of indels (Figure 33C) 
HEK293 cells were transfected with plasmids encoding WT (cas9‐00) or mutated (cas9-
11) cas9 gene, and 20-nt gRNA targeting a gene encoding structural proteins (EMX1). 
The amount of Cas9-induced indels in the targeted region was measured. Genomic DNA 
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from the heterogeneous population of Cas9-targeted cells is amplified by PCR to 
determine the indel percentage in EMX1 loci, amplicons are then sequenced. Cas9-
mediated cleavage efficiency (percentage indel) is calculated on the basis of the fraction 
of cleaved DNA, as determined by sequencing.  
 
 
 
 
 
Figure 33. Comparable functionality of mutated Cas9 and wild-type Cas9. A) 
Measuring activation by IRFP signal intensity. B) Measuring repression of target DNA by YFP 
signal intensity.   
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Figure 34. Mutated Cas9 proteins recognize and bind to their target DNAs, leading 
to enhanced endogenous target gene expression or introduction of indels. Activation and 
cutting of endogenous genes in HEK293T cells: (A and B) RNA expression of cells transfected 
with (i) indicated Cas9 proteins, (ii) MS2‐P65‐HSF1, and (iii) 14-nt gRNA targeting TTN (A) 
and MIAT (B). (C) Indel formation percentage of HEK293T cells transfected with the indicated 
Cas9 proteins and 20-nt gRNA targeting EMX1. Data indicate mean +SD. (n = 3 independent 
transfections). 
 
 
 
 
3.3.5. Detection and Reduction of Epitope specific CD8 Response  
 
Antigen-specific T cells were expanded from peptide-spiked autologous APCs 
after 18 days in two rounds of stimulation and analyzed for peptide 94 or 85-specific CD8 
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response.  To achieve this goal, we measured CD137 as an early marker of T cell 
activation, detected 48 hours after the second round of stimulation (Wolfl et al., 2007).  
When peripheral blood (PB) T cells were stimulated with APCs spiked with peptide 94, the 
percentage of CD8+ CD137+ T cells was 4.37% (Figure 35A), while it decreased to 2.74% 
(Figure 35B) when peptide 24 (mutated peptide 94) was used.  
 
 
Figure 35. T cell activation with Cas9 epitope and mutated epitope. A) CD8+CD137 
positive population is demonstrated after exposure to peptide 94. B) CD137 positive population is 
demonstrated after exposure to mutated peptide 94 (peptide 24).  
 
 
We quantified the T cell response against epitope 85 by staining with a specific 
MHC-pentamer.  The percentage of CD8+ pentamer+ T cell population was 3.09% 
(Figure 36A) when PB T cells were stimulated with APCs spiked with peptide 85 and it 
dropped to 0.3% (Figure 36B) when the mutated peptide (peptide 21) was used.   
 
76 
 
Figure 36. Epitope specific CD8 T cell response to epitope 85. CD8+Pet+ represents 
the epitope specific T cell response. Peptide 21 is the mutated form of peptide 85 and used as a 
control. 
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3.4. DISCUSSION 
 
The CRISPR-Cas9 system is being applied for a vast variety of research purposes 
and exciting pre-clinical results are leading its way towards clinical use. Targeted genetic 
modification is a powerful tool that can be applied for the treatment or prevention of 
diseases involving somatic mutations. Examples are current human cancer clinical trials 
including lung, prostate, and renal cell cancers. Genetic engineering with CRISPR-Cas9 
has successfully targeted convertase/subtilisin/kexin type 9 (PCSK9) to deregulate 
cholesterol metabolism in mouse hepatocytes (Ding et al., 2014). Another application 
involves improvement of muscle function in live animals by introducing dystrophin gene in 
the case of dystrophin deficiency (Long et al., 2016). Target discovery of p53 reactivating 
drugs using CRISPR-Cas9 is one of the many research applications of this gene editing 
system (Wanzel et al., 2015).  
Clinical challenges and ethical questions have been intensely discussed as the 
CRISPR-Cas9 field is growing fast (Cox, Platt, & Zhang, 2015). Non-specific Cas9 
nuclease cleavage has been reported to be more frequent in humans in comparison to 
other models (Hwang et al., 2013; L. Yang et al., 2015). Recent work suggests that the 
HDR-NHEJ ratio, a measure of efficacy, can be improved through three factors - DNA 
repair machinery, better delivery methods, and timing (Maeder & Gersbach, 2016). The 
delivery method has always been a challenge in gene therapy for several reasons. These 
include low transfection efficiency in primary cells, random plasmid insertion and 
integration, the cytotoxicity associated with the use of DNA, and bacterial DNA sequences 
present in plasmid backbones (Maeder & Gersbach, 2016; H. Wang, La Russa, & Qi,  
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2016). Adeno-associated virus (AAV)-based vectors are favored for use in somatic gene 
therapy as they are not pathogenic and are capable of targeting non-dividing cells. 
However, the packaging limit is problematic, given the large coding sequence of SpCas9 
and the sgRNA. Unlike the mild immune response induced by adenoviral vectors that has 
been extensively studied, the immunogenicity of the bacterial Cas9 protein is unknown in 
humans. Success in clinical translation of targeted gene therapy is highly limited by the 
efficacy and undesired immune response.  
In this project, pre-existing T cell and B cell responses to Cas9 is assessed in 
humans for the first time. A healthy population is screened for Cas9-specific serum 
antibody and CD8+ T cell responses. At least 21% of the healthy individuals screened had 
antibodies to Cas9 and strikingly 10 out of 12 donors had common reactivity to two 
epitopes of Cas9, 85 and 94. Here, we did not find any association between the T cell and 
B cell response to Cas9 (data not shown).  
Cas9 B cell epitopes have been mapped in mice (Chew et al., 2016), while T cell 
epitope mapping is yet to be done. However, the Identified epitopes are not expected to 
be shared with humans, few overlapping epitopes has been observed between animal 
model and human antigens (Mazor et al., 2015). Ideally, if the T cell and B cell epitopes 
share sequences, mutating the epitope can result in a major reduction of the immune 
recognition. Yet disrupting the T cell epitopes of LMB-T20 (a recombinant immunotoxin), 
when there was pre-existing immune response, prevented B cell activation. (Mazor et al., 
2015). Furthermore, Mazor et al. demonstrated that de-immunization of SS1P (a 
recombinant immunotoxin), by removing the dominant T cell epitopes prevented serum 
antibody production.  In this study, we focused on pre-existing immune response and 
further studies are needed for post-treatment T cell response induction. The question of 
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whether persistent expression of a transgene increases the tolerance or unleashes 
cytokine secretion needs to be examined. 
 
 
 
 
Figure 37. SpCas9 protein domains and epitope 85 and 94 locations on the protein. 
 
Here, we designed a method that requires the least changes in the protein 
sequence to evade T cell recognition without disrupting the protein function. First, we 
limited the changes to the immunodominant epitopes as identified by our prediction model 
and validated by ELISpot. Second, we limited the mutation to the second residue of these 
epitopes, being one of two anchor residues necessary for binding to the MHC groove 
(Chowell et al., 2015). After mutation, the peptides were not recognized by T cells (Figure 
31) and their binding scores (Sb) significantly increased. Fortunately, the identified 
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epitopes were not located in functionally critical positions of Cas9 (Figure 37) and the 
mutated protein preserved its function (Figure 33). For further validation of CD8 epitope-
specific response, T cells were stained with MHC pentamer and peptide 85-specific CD8+ 
T cells were quantified (Figure 36). 
Conventional methods of testing synthetic peptides to identify immunogenic 
epitopes are helpful for proof of principle but require an antigen presenting model for CD8 
response. Antigen presenting cells (APCs) are a good model as we can directly control 
the transfection load of the exogenous gene. T cells will be stimulated with autologous 
APCs transfected with Cas9 mRNA and T cell activation will be measured using specific 
markers. Unfortunately, these experiments were not done in the time frame of this thesis.  
Future studies will include the comparison of the antigenicity of APCs presenting 
Cas9 epitopes with APCs expressing mutated Cas9. The Cas9 sequence is made up of 
1368 amino acids, with about 100 predicted HLA-A*02:01 high binding epitopes. It is 
probable that removing two epitopes will significantly decrease the T cell recognition but 
not completely abolish it. Another limitation to the project is the diversity of MHCs, the 
most polymorphic gene variants, in individuals. HLA-A*02:01 is the most common MHC 
type in Caucasians but a comprehensive immunogenicity evaluation should take all the 
HLAs into account if feasible.  
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APPENDIX A 
LIST OF ENRICHED PATHWAYS MUTANT P53 MCF10AS.  
GENE ENRICHMENT ANALYSIS OF DIFFERENTIALLY EXPRESSED GENES IN 
MUTANT P53 MCF10AS VS. WT P53 MCF10A.  
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Category 
 Pathways enriched in R273H mp53 
vs wtp53.MCF10A 
P-Value FE 
REACTOME R-HSA-2424491:DAP12 signaling 0.037 2.47 
KEGG hsa04144:Endocytosis 0.037 1.38 
REACTOME R-HSA-1566948:Elastic fiber formation 0.038 3.08 
REACTOME R-HSA-380270:Recruitment of mitotic centrosome proteins and 
complexes 
0.038 1.78 
REACTOME R-HSA-512988:Interleukin-3, 5 and GM-CSF signaling 0.038 2.70 
KEGG hsa04120:Ubiquitin mediated proteolysis 0.042 1.55 
REACTOME R-HSA-383280:Nuclear Receptor transcription pathway 0.043 2.00 
REACTOME R-HSA-2995383:Initiation of Nuclear Envelope Reformation 0.044 3.56 
KEGG hsa04910:Insulin signaling pathway 0.045 1.54 
REACTOME R-HSA-166166:MyD88-independent TLR3/TLR4 cascade 0.046 4.63 
REACTOME R-HSA-5675221:Negative regulation of MAPK pathway 0.047 2.19 
REACTOME R-HSA-166016:Toll Like Receptor 4 (TLR4) Cascade 0.047 2.92 
REACTOME R-HSA-2565942:Regulation of PLK1 Activity at G2/M 
Transition 
0.049 1.68 
KEGG hsa05166:HTLV-I infection 0.051 1.36 
KEGG hsa05222:Small cell lung cancer 0.053 1.70 
REACTOME R-HSA-909733:Interferon alpha/beta signaling 0.053 1.80 
REACTOME R-HSA-937041:IKK complex recruitment mediated by RIP1 0.054 2.49 
REACTOME R-HSA-193775:Synthesis of bile acids and bile salts via 24-
hydroxycholesterol 
0.056 3.31 
REACTOME R-HSA-5362517:Signaling by Retinoic Acid 0.057 2.78 
KEGG hsa04151:PI3K-Akt signaling pathway 0.059 1.29 
REACTOME R-HSA-5620912:Anchoring of the basal body to the plasma 
membrane 
0.060 1.61 
KEGG hsa04512:ECM-receptor interaction 0.062 1.66 
KEGG hsa04914:Progesterone-mediated oocyte maturation 0.062 1.66 
KEGG hsa05230:Central carbon metabolism in cancer 0.062 1.81 
KEGG hsa04660:T cell receptor signaling pathway 0.063 1.59 
REACTOME R-HSA-3000170:Syndecan interactions 0.064 2.40 
96 
REACTOME R-HSA-2993913:Clearance of Nuclear Envelope Membranes 
from Chromatin 
0.064 4.11 
REACTOME R-HSA-425986:Sodium/Proton exchangers 0.064 4.11 
REACTOME R-HSA-549127:Organic cation transport 0.064 4.11 
REACTOME R-HSA-114608:Platelet degranulation 0.066 1.56 
KEGG hsa04540:Gap junction 0.067 1.65 
KEGG hsa05211:Renal cell carcinoma 0.068 1.78 
REACTOME R-HSA-2559580:Oxidative Stress Induced Senescence 0.068 1.50 
KEGG hsa04145:Phagosome 0.069 1.45 
REACTOME R-HSA-3772470:Negative regulation of TCF-dependent 
signaling by WNT ligand antagonists 
0.070 3.08 
KEGG hsa04150:mTOR signaling pathway 0.072 1.83 
KEGG hsa05203:Viral carcinogenesis 0.075 1.37 
REACTOME R-HSA-216083:Integrin cell surface interactions 0.076 1.61 
REACTOME R-HSA-445355:Smooth Muscle Contraction 0.077 2.12 
REACTOME R-HSA-975634:Retinoid metabolism and transport 0.077 1.98 
REACTOME R-HSA-912631:Regulation of signaling by CBL 0.081 2.52 
KEGG hsa00310:Lysine degradation 0.083 1.86 
KEGG hsa04915:Estrogen signaling pathway 0.084 1.56 
REACTOME R-HSA-1234158:Regulation of gene expression by Hypoxia-
inducible Factor 
0.084 3.70 
REACTOME R-HSA-5210891:Uptake and function of anthrax toxins 0.084 3.70 
REACTOME R-HSA-74749:Signal attenuation 0.084 3.70 
REACTOME R-HSA-1963642:PI3K events in ERBB2 signaling 0.086 2.89 
REACTOME R-HSA-2559584:Formation of Senescence-Associated 
Heterochromatin Foci (SAHF) 
0.086 2.89 
REACTOME R-HSA-446652:Interleukin-1 signaling 0.087 2.06 
 
Category 
Pathways enriched in G245S mp53 
vs wtp53.MCF10A 
P-Value FE 
REACTOME  hsa909733:Interferon alpha/beta signaling 9.10E-12 3.96 
REACTOME  hsa877300:Interferon gamma signaling 4.47E-06 2.63 
KEGG  hsa05168:Herpes simplex infection 7.32E-06 2.10 
97 
REACTOME  hsa1236977:Endosomal/Vacuolar pathway 1.33E-04 5.71 
KEGG  hsa04142:Lysosome 5.21E-04 2.07 
KEGG  hsa05164:Influenza A 8.18E-04 1.83 
KEGG  hsa04145:Phagosome 8.62E-04 1.89 
KEGG  hsa05160:Hepatitis C 9.79E-04 1.96 
KEGG  hsa05169:Epstein-Barr virus infection 0.0019 1.73 
KEGG  hsa04012:ErbB signaling pathway 0.0030 2.11 
KEGG  hsa05133:Pertussis 0.0036 2.19 
REACTOME  hsa983231:Factors involved in megakaryocyte development and 
platelet production 
0.0045 1.84 
KEGG  hsa04620:Toll-like receptor signaling pathway 0.0055 1.91 
KEGG  hsa01100:Metabolic pathways 0.0066 1.20 
KEGG  hsa05161:Hepatitis B 0.0070 1.73 
REACTOME  hsa983168:Antigen processing: Ubiquitination & Proteasome 
degradation 
0.0076 1.47 
KEGG  hsa05205:Proteoglycans in cancer 0.0078 1.59 
KEGG  hsa05162:Measles 0.0091 1.74 
KEGG  hsa04722:Neurotrophin signaling pathway 0.011 1.77 
REACTOME  hsa112409:RAF-independent MAPK1/3 activation 0.012 3.96 
REACTOME  R-HSA-212436:Generic Transcription Pathway 0.013 1.37 
KEGG  hsa04630:Jak-STAT signaling pathway 0.013 1.66 
REACTOME  hsa112411:MAPK1 (ERK2) activation 0.014 4.76 
KEGG  hsa05212:Pancreatic cancer 0.014 2.08 
KEGG  hsa05152:Tuberculosis 0.014 1.58 
KEGG  hsa04064:NF-kappa B signaling pathway 0.016 1.89 
REACTOME  hsa982772:Growth hormone receptor signaling 0.017 2.86 
KEGG  hsa05145:Toxoplasmosis 0.018 1.72 
REACTOME  hsa1989781:PPARA activates gene expression 0.020 1.67 
KEGG  hsa04010:MAPK signaling pathway 0.020 1.44 
REACTOME  hsa110056:MAPK3 (ERK1) activation 0.022 4.29 
KEGG  hsa04668:TNF signaling pathway 0.023 1.73 
REACTOME  hsa983170:Antigen Presentation: Folding, assembly and peptide 
loading of class I MHC 
0.026 2.64 
REACTOME  hsa912694:Regulation of IFNA signaling 0.026 2.64 
98 
KEGG  hsa04380:Osteoclast differentiation 0.027 1.62 
KEGG  hsa05140:Leishmaniasis 0.029 1.90 
REACTOME  R-HSA-5620916:VxPx cargo-targeting to cilium 0.029 2.86 
REACTOME  R-HSA-1059683:Interleukin-6 signaling 0.031 3.90 
REACTOME  R-HSA-2562578:TRIF-mediated programmed cell death 0.031 3.90 
REACTOME  R-HSA-937072:TRAF6 mediated induction of TAK1 complex 0.040 3.03 
KEGG  hsa04070:Phosphatidylinositol signaling system 0.043 1.67 
REACTOME  R-HSA-5620924:Intraflagellar transport 0.044 1.91 
KEGG  hsa04146:Peroxisome 0.044 1.74 
REACTOME  R-HSA-2032785:YAP1- and WWTR1 (TAZ)-stimulated gene expression 0.045 2.37 
REACTOME  R-HSA-1566948:Elastic fibre formation 0.050 2.86 
KEGG  hsa04210:Apoptosis 0.051 1.87 
REACTOME  R-HSA-5656169:Termination of translesion DNA synthesis 0.053 2.29 
KEGG  hsa05219:Bladder cancer 0.056 2.12 
REACTOME  R-HSA-166166:MyD88-independent TLR3/TLR4 cascade 0.056 4.29 
KEGG  hsa04917:Prolactin signaling pathway 0.059 1.77 
KEGG  hsa00562:Inositol phosphate metabolism 0.059 1.77 
REACTOME  R-HSA-5620912:Anchoring of the basal body to the plasma membrane 0.060 1.57 
KEGG  hsa05220:Chronic myeloid leukemia 0.064 1.74 
REACTOME  R-HSA-168138:Toll Like Receptor 9 (TLR9) Cascade 0.069 6.43 
REACTOME  R-HSA-204174:Regulation of pyruvate dehydrogenase (PDH) complex 0.071 3.06 
REACTOME  R-HSA-1660516:Synthesis of PIPs at the early endosome membrane 0.071 3.06 
REACTOME  R-HSA-194840:Rho GTPase cycle 0.071 1.48 
KEGG  hsa00760:Nicotinate and nicotinamide metabolism 0.072 2.33 
REACTOME  R-HSA-264876:Insulin processing 0.074 2.31 
REACTOME  R-HSA-6788467:IL-6-type cytokine receptor ligand interactions 0.075 2.57 
KEGG  hsa05203:Viral carcinogenesis 0.075 1.37 
KEGG  hsa00480:Glutathione metabolism 0.076 1.89 
REACTOME  R-HSA-1169408:ISG15 antiviral mechanism 0.077 1.64 
REACTOME  R-HSA-549127:Organic cation transport 0.077 3.81 
REACTOME  R-HSA-727802:Transport of nucleotide sugars 0.077 3.81 
KEGG  hsa04144:Endocytosis 0.081 1.31 
REACTOME  R-HSA-912526:Interleukin receptor SHC signaling 0.086 2.22 
REACTOME  R-HSA-140534:Ligand-dependent caspase activation 0.088 2.86 
99 
REACTOME  R-HSA-4419969:Depolymerisation of the Nuclear Lamina 0.088 2.86 
REACTOME  R-HSA-975577:N-Glycan antennae elongation 0.088 2.86 
REACTOME  R-HSA-428540:Activation of Rac 0.088 2.86 
REACTOME  R-HSA-1810476:RIP-mediated NFkB activation via ZBP1 0.089 2.45 
 
Category 
Pathways enriched in R248Q mp53 
vs wtp53.MCF10A 
P-Value FE 
KEGG  hsa05200:Pathways in cancer 2.85E-04 1.61 
KEGG  hsa04151:PI3K-Akt signaling pathway 7.34E-04 1.61 
KEGG  hsa04360:Axon guidance 8.21E-04 2.10 
KEGG  hsa04380:Osteoclast differentiation 1.27E-03 2.04 
KEGG  hsa05416:Viral myocarditis 1.31E-03 2.73 
KEGG  hsa04510:Focal adhesion 1.42E-03 1.78 
REACTOME  R-HSA-2129379:Molecules associated with elastic fibres 1.69E-03 3.17 
REACTOME  R-HSA-383280:Nuclear Receptor transcription pathway 1.74E-03 2.79 
KEGG  hsa04015:Rap1 signaling pathway 1.95E-03 1.75 
KEGG  hsa05222:Small cell lung cancer 3.29E-03 2.22 
KEGG  hsa05205:Proteoglycans in cancer 3.40E-03 1.72 
KEGG  hsa05230:Central carbon metabolism in cancer 3.93E-03 2.43 
KEGG  hsa05212:Pancreatic cancer 4.52E-03 2.39 
KEGG  hsa04668:TNF signaling pathway 5.94E-03 1.99 
REACTOME  R-HSA-114608:Platelet degranulation 7.84E-03 1.94 
KEGG  hsa04210:Apoptosis 8.20E-03 2.33 
REACTOME  R-HSA-3000170:Syndecan interactions 9.02E-03 3.24 
KEGG  hsa05219:Bladder cancer 9.21E-03 2.71 
KEGG  hsa04145:Phagosome 9.41E-03 1.74 
KEGG  hsa05140:Leishmaniasis 9.72E-03 2.19 
REACTOME  hsa2151201:Transcriptional activation of mitochondrial bio 1.03E-02 2.67 
KEGG  hsa04142:Lysosome 1.11E-02 1.84 
KEGG  hsa04010:MAPK signaling pathway 1.21E-02 1.52 
KEGG  hsa00561:Glycerolipid metabolism 1.29E-02 2.30 
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KEGG  hsa04066:HIF-1 signaling pathway 1.33E-02 1.93 
REACTOME  RHSA-446107:Type I hemidesmosome assembly 1.35E-02 4.97 
REACTOME  R-HSA-3000178:ECM proteoglycans 1.74E-02 2.04 
REACTOME  R-HSA-1236977:Endosomal/Vacuolar pathway 1.88E-02 4.56 
KEGG  hsa01100:Metabolic pathways 1.90E-02 1.19 
REACTOME  R-HSA-1566948:Elastic fibre formation 1.97E-02 3.64 
KEGG  hsa05166:HTLV-I infection 2.10E-02 1.48 
REACTOME  R-HSA-216083:Integrin cell surface interactions 2.32E-02 1.91 
KEGG  hsa05215:Prostate cancer 2.44E-02 1.89 
REACTOME  R-HSA-1971475:A GAG synthesis 2.68E-02 2.94 
REACTOME  R-HSA-194840:Rho GTPase cycle 2.79E-02 1.70 
KEGG  hsa04150:mTOR signaling pathway 3.22E-02 2.11 
REACTOME  R-HSA-3928662:EPHB-mediated forward signaling 3.39E-02 2.34 
KEGG  hsa04115:p53 signaling pathway 3.52E-02 1.99 
KEGG  hsa05120:Epithelial cell signaling in Helicobacter pylori  3.52E-02 1.99 
KEGG  hsa05231:Choline metabolism in cancer 3.53E-02 1.76 
KEGG  hsa04350:TGF-beta signaling pathway 3.59E-02 1.85 
KEGG  hsa02010:ABC transporters 3.99E-02 2.27 
REACTOME  R-HSA-446652:Interleukin-1 signaling 4.15E-02 2.43 
REACTOME  R-HSA-2214320:Anchoring fibril formation 4.17E-02 3.64 
REACTOME  R-HSA-428543:Inactivation of Cdc42 and Rac 4.20E-02 4.86 
REACTOME  R-HSA-2408550:Metabolism of ingested H2SeO4 and 
H2SeO3 into H2Se 
4.41E-02 8.20 
REACTOME  R-HSA-5365859:RA biosynthesis pathway 4.46E-02 2.98 
REACTOME  R-HSA-1474228:Degradation of the extracellular matrix 4.56E-02 1.85 
KEGG  hsa04512:ECM-receptor interaction 4.59E-02 1.79 
KEGG  hsa05150:Staphylococcus aureus infection 4.95E-02 2.06 
KEGG  hsa05134:Legionellosis 4.95E-02 2.06 
KEGG  hsa05323:Rheumatoid arthritis 4.97E-02 1.77 
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KEGG  hsa00340:Histidine metabolism 4.98E-02 2.90 
REACTOME  R-HSA-112043:PLC beta mediated events 5.17E-02 3.42 
REACTOME  R-HSA-202733:Cell surface interactions at the vascular wall 5.41E-02 2.02 
KEGG  hsa00512:Mucin type O-Glycan biosynthesis 5.45E-02 2.51 
REACTOME  R-HSA-877300:Interferon gamma signaling 5.56E-02 1.74 
KEGG  hsa00280:Valine, leucine and isoleucine degradation 5.59E-02 2.13 
REACTOME  R-HSA-418889:Ligand-independent caspase activation 5.60E-02 4.37 
KEGG  hsa04960:Aldosterone-regulated sodium reabsorption 5.61E-02 2.28 
REACTOME  hsa352230:Amino acid transport across the plasma mem 5.83E-02 2.47 
KEGG  hsa00450:Selenocompound metabolism 5.99E-02 3.27 
KEGG  hsa00910:Nitrogen metabolism 5.99E-02 3.27 
KEGG  hsa05221:Acute myeloid leukemia 6.02E-02 1.98 
KEGG  hsa00520:Amino sugar and nucleotide sugar metabolism 6.21E-02 2.08 
REACTOME  R-HSA-1369062:ABC transporters in lipid homeostasis 6.29E-02 3.22 
KEGG  hsa00380:Tryptophan metabolism 6.30E-02 2.22 
KEGG  hsa04071:Sphingolipid signaling pathway 7.01E-02 1.57 
KEGG  hsa05332:Graft-versus-host disease 7.05E-02 2.36 
REACTOME  R-HSA-71240:Tryptophan catabolism 7.19E-02 3.98 
REACTOME  R-HSA-351906:Apoptotic cleavage of cell adhesion proteins 7.19E-02 3.98 
REACTOME  R-HSA-200425:Import of palmitoyl-CoA into the mitochondri 7.19E-02 3.98 
REACTOME  R-HSA-1266695:Interleukin-7 signaling 7.19E-02 3.98 
REACTOME  R-HSA-210991:Basigin interactions 7.19E-02 2.62 
REACTOME  R-HSA-4085001:Sialic acid metabolism 7.52E-02 2.32 
REACTOME  R-HSA-983170:Antigen Presentation: Folding, assembly 
and peptide loading of class I MHC 
8.27E-02 2.52 
KEGG  hsa04514:Cell adhesion molecules (CAMs) 8.46E-02 1.49 
KEGG  hsa00350:Tyrosine metabolism 8.90E-02 2.22 
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Category 
Pathways enriched in Y234C mp53 
vs wtp53.MCF10A 
P-Value FE 
REACTOME  R-HSA-212436:Generic Transcription Pathway 0.00064 1.65 
REACTOME  R-HSA-191273:Cholesterol biosynthesis 0.00069 4.92 
REACTOME  R-HSA-2426168:Activation of gene expression by SREBF  0.0016 3.22 
KEGG  hsa05166:HTLV-I infection 0.0020 1.73 
REACTOME  hsa139915:Activation of PUMA and translocation to 
mitochondria 
0.0023 7.69 
REACTOME  hsa174417:Telomere C-strand (Lagging Strand) Synthesis 0.0047 9.84 
KEGG  hsa03440:Homologous recombination 0.0052 3.60 
KEGG  hsa04012:ErbB signaling pathway 0.0059 2.25 
KEGG  hsa03430:Mismatch repair 0.0064 3.97 
KEGG  hsa01100:Metabolic pathways 0.0065 1.24 
KEGG  hsa05202:Transcriptional misregulation in cancer 0.0088 1.78 
REACTOME  hsa174414:Processive synthesis on the C-strand of the 
telomere 
0.0089 8.20 
KEGG  hsa04666:Fc gamma R-mediated phagocytosis 0.011 2.17 
REACTOME  hsa1368082:RORA activates gene expression 0.019 3.19 
REACTOME  hsa69091:Polymerase switching 0.022 4.39 
REACTOME  hsa174411:Polymerase switching on the C-strand of the 
telomere 
0.022 4.39 
KEGG  hsa05132:Salmonella infection 0.023 2.04 
KEGG  hsa05212:Pancreatic cancer 0.025 2.21 
REACTOME  hsa2032785:YAP1- and WWTR1 (TAZ)-stimulated gene 
expression 
0.027 2.97 
REACTOME  hsa1912408:Pre-NOTCH Transcription and Translation 0.027 2.97 
KEGG  hsa05161:Hepatitis B 0.028 1.71 
KEGG  hsa00564:Glycerophospholipid metabolism 0.028 1.92 
REACTOME  hsa428540:Activation of Rac 0.029 4.10 
KEGG  hsa05120:Epithelial cell signaling in Helicobacter pylori 
infection 
0.030 2.14 
KEGG  hsa04668:TNF signaling pathway 0.031 1.84 
REACTOME  hsa2559585:Oncogene Induced Senescence 0.031 2.87 
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KEGG  hsa05205:Proteoglycans in cancer 0.031 1.56 
KEGG  hsa04810:Regulation of actin cytoskeleton 0.032 1.54 
REACTOME  hsa111448:Activation of NOXA and translocation to 
mitochondria 
0.035 9.22 
KEGG  hsa00910:Nitrogen metabolism 0.036 3.83 
KEGG  hsa03410:Base excision repair 0.037 2.77 
REACTOME  hsa5656169:Termination of translesion DNA synthesis 0.041 2.69 
REACTOME  hsa69183:Processive synthesis on the lagging strand 0.042 4.92 
REACTOME  hsa174437:Removal of the Flap Intermediate  0.042 4.92 
REACTOME  hsa-74749:Signal attenuation 0.042 4.92 
REACTOME  hsa400253:Circadian Clock 0.042 2.26 
KEGG  hsa05231:Choline metabolism in cancer 0.044 1.81 
KEGG  hsa04210:Apoptosis 0.045 2.10 
KEGG  hsa04152:AMPK signaling pathway 0.045 1.71 
REACTOME  hsa5696397:Gap-filling DNA repair synthesis and ligation 
in GG-NER 
0.047 2.95 
REACTOME  hsa383280:Nuclear Receptor transcription pathway 0.052 2.17 
REACTOME  hsa2586552:Signaling by Leptin 0.054 4.47 
REACTOME  R-HSA-74713: IRS activation 0.056 7.38 
KEGG  hsa04621:NOD-like receptor signaling pathway 0.056 2.13 
KEGG  hsa04360:Axon guidance 0.060 1.64 
REACTOME  hsa3928664:Ephrin signaling 0.063 3.24 
REACTOME  hsa1475029: Reversible hydration of carbon dioxide 0.068 4.10 
KEGG  hsa04115:p53 signaling pathway 0.068 1.95 
KEGG  hsa04390:Hippo signaling pathway 0.069 1.55 
KEGG  hsa04932:Non-alcoholic fatty liver disease (NAFLD) 0.069 1.55 
REACTOME  hsa1989781:PPARA activates gene expression 0.073 1.63 
REACTOME  R-HSA-3560783:Defective B4GALT7 causes EDS 0.074 3.07 
REACTOME  R-HSA-189483: Heme degradation 0.079 6.15 
KEGG  hsa04010:MAPK signaling pathway 0.080 1.38 
KEGG  hsa00900:Terpenoid backbone biosynthesis 0.083 2.96 
REACTOME  hsa1483213:Synthesis of PE 0.083 3.78 
REACTOME  hsa112409:RAF-independent MAPK1/3 activation 0.083 3.78 
REACTOME  hsa5675221:Negative regulation of MAPK pathway 0.084 2.27 
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REACTOME  hsa5651801:PCNA-Dependent Long Patch Base E Repair 0.085 2.93 
REACTOME  hsa5621575:CD209 (DC-SIGN) signaling 0.085 2.93 
KEGG  hsa00562:Inositol phosphate metabolism 0.091 1.84 
KEGG  hsa04014:Ras signaling pathway 0.096 1.38 
 
